phentermine has been researched along with Weight Reduction in 138 studies
Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This pilot study evaluated whether adding phentermine to liraglutide would induce further weight loss in participants who had previously lost weight with liraglutide alone." | 9.30 | Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial. ( Alamuddin, N; Berkowitz, RI; Chao, AM; Gruber, K; Leonard, S; Tronieri, JS; Wadden, TA; Walsh, OA, 2019) |
| "Phentermine is thought to cause weight loss through a reduction in hunger." | 9.22 | Greater hunger and less restraint predict weight loss success with phentermine treatment. ( Bechtell, JL; Cornier, MA; Eckel, RH; Ferland, A; Mcnair, B; Thomas, EA, 2016) |
| "In a 12-week randomized, double-blind, placebo-controlled clinical trial, 77 adults with obesity received either phentermine or placebo." | 9.22 | Effects of a meal replacement system alone or in combination with phentermine on weight loss and food cravings. ( Aréchiga, AL; Bellinger, DL; Berk, LS; Daher, NS; Davis, WL; Hermé, AC; Moldovan, CP; Peters, WR; Schneider, LE; Weldon, AJ, 2016) |
| " Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has previously shown significant weight loss compared with placebo in a 56-wk study in overweight and obese subjects with ≥2 weight-related comorbidities." | 9.16 | Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. ( Allison, DB; Bowden, CH; Day, WW; Gadde, KM; Garvey, WT; Look, M; Peterson, CA; Ryan, DH; Schwiers, M, 2012) |
| " We therefore assessed the efficacy and safety of two doses of phentermine plus topiramate controlled-release combination as an adjunct to diet and lifestyle modification for weight loss and metabolic risk reduction in individuals who were overweight and obese, with two or more risk factors." | 9.15 | Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. ( Allison, DB; Day, WW; Gadde, KM; Peterson, CA; Ryan, DH; Schwiers, ML; Troupin, B, 2011) |
| "To evaluate the efficacy and safety of a newly developed formulation of phentermine diffuse-controlled release (DCR) in patients with obesity." | 9.14 | Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity. ( Kang, JG; Kang, JH; Park, CY; Park, SW; Park, YW, 2010) |
| "Phentermine/topiramate has considerable benefit in reducing body weight, and the efficacy was closely related to the dosage." | 9.12 | Efficacy and Safety of Phentermine/Topiramate in Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis. ( Lai, C; Lei, XG; Ruan, JQ; Sun, Z; Yang, X, 2021) |
| " Phentermine and topiramate extended-release (phentermine/topiramate ER) has recently been approved in the USA for chronic weight management in obese adults and overweight adults with weight-related co-morbidities in conjunction with a reduced-calorie diet and increased physical activity." | 8.89 | Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. ( Garvey, WT, 2013) |
| " Food and Drug Administration approved phentermine-topiramate for obesity in 2012 and required a Risk Evaluation and Mitigation Strategy (REMS) to prevent prenatal exposure." | 8.31 | Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy. ( Brown, JD; Donahoo, WT; Hampp, C; Sarayani, A; Winterstein, AG, 2023) |
| " The objectives of our study are to describe weight loss, pregnancy rates, and live birth rates after short-term phentermine use in women with obesity and infertility." | 7.96 | A Retrospective Study Examining Phentermine on Preconception Weight Loss and Pregnancy Outcomes. ( Chang, JJ; Kim, SH; Lathi, RB, 2020) |
| "Phentermine/topiramate combination therapy resulted in significant weight loss and improvements in cardiometabolic risk factors in patients with obesity/overweight in two published 56-week randomized, placebo-controlled trials (EQUIP and CONQUER)." | 7.83 | Health-related quality of life in two randomized controlled trials of phentermine/topiramate for obesity: What mediates improvement? ( Crosby, RD; Gadde, KM; Kolotkin, RL; Peterson, CA, 2016) |
| "Phase 3 clinical trial results reveal that Qsymia is a clinically effective long-term treatment for obesity, but whether this treatment is cost-effective compared to a diet and lifestyle intervention has yet to be explored." | 7.81 | Cost-Effectiveness Analysis of Qsymia for Weight Loss. ( Finkelstein, EA; Karnawat, S; Kruger, E, 2015) |
| "Phentermine abuse or psychological dependence (addiction) does not occur in patients treated with phentermine for obesity." | 7.80 | Addiction potential of phentermine prescribed during long-term treatment of obesity. ( De Marco, DG; Greenway, FL; Haggard, M; Hendricks, EJ; Hendricks, MJ; Istratiy, Y; Mitchell, CL; Schmidt, SL; Souter, S; Srisurapanont, M, 2014) |
| "There is a perception that phentermine pharmacotherapy for obesity increases blood pressure and heart rate (HR), exposing treated patients to increased cardiovascular risk." | 7.77 | Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. ( Greenway, FL; Gupta, AK; Hendricks, EJ; Westman, EC, 2011) |
| "A 35-year-old woman taking phentermine for weight loss presented with altered mental status and 2 witnessed generalized seizures." | 7.77 | Posterior reversible encephalopathy syndrome in the context of phentermine use resulting in intracranial hemorrhage. ( Singh, H; Verro, P; Wong, VS, 2011) |
| " We present the unique case of a Choctaw lady with morbid obesity who has shown a profound response to pharmacotherapy with phentermine." | 7.75 | A case of profound weight loss secondary to use of phentermine. ( Koch, CA; McDonald, A; Melcescu, E; Uwaifo, GI, 2009) |
| "Phentermine and fenfluramine are widely used in the treatment of obesity." | 7.70 | Lower dosages of phentermine-fenfluramine given in the afternoon: five cases with significant weight loss. ( Katz, DA; Maloney, MJ; McConville, BJ; Sutkamp, JC, 1999) |
| " Dry mouth and insomnia were the only statistically significant adverse events that occurred more frequently in phentermine group." | 6.72 | Effects on weight reduction and safety of short-term phentermine administration in Korean obese people. ( Cho, HJ; Kang, HC; Kim, KK; Lee, KR; Youn, BB, 2006) |
| " Cardiovascular data associated with long-term use of phentermine and topiramate extended-release indicate that this combination may be a safe and effective option for reducing weight in overweight/obese patients at low-to-intermediate cardiovascular risk." | 6.50 | Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. ( Astrup, A; Day, WW; Engeli, S; Finer, N; Jordan, J; Narkiewicz, K, 2014) |
| "The treatment of obesity is often met with a myriad of challenges in the primary care setting." | 6.50 | Combination phentermine/topiramate for obesity treatment in primary care: a review. ( Gadde, KM; Xiong, GL, 2014) |
| "Qsymia is a combination of phentermine and topiramate used for obesity treatment." | 6.49 | Phentermine and topiramate extended-release for the obesity: new kids on the block. ( Kallikazaros, I; Kallistratos, MS; Katsi, V; Makris, T; Manolis, AJ; Marketou, M; Tousoulis, D; Vardas, P, 2013) |
| "Orlistat treatment improves oxysterol metabolism in overweight and obese adults." | 5.51 | The Effect of Orlistat on Sterol Metabolism in Obese Patients. ( Choi, MH; Kwon, GE; Kwon, YJ; Lee, HS; Lee, JW, 2022) |
| "Phentermine use was associated with a greater percent change in BMI at 1 month (-1." | 5.46 | Effect of phentermine on weight reduction in a pediatric weight management clinic. ( Fox, CK; Gross, A; Kaizer, A; Kelly, AS; Rudser, KD; Ryder, JR, 2017) |
| "This pilot study evaluated whether adding phentermine to liraglutide would induce further weight loss in participants who had previously lost weight with liraglutide alone." | 5.30 | Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial. ( Alamuddin, N; Berkowitz, RI; Chao, AM; Gruber, K; Leonard, S; Tronieri, JS; Wadden, TA; Walsh, OA, 2019) |
| "Phentermine added to lorcaserin enhanced short-term weight loss but did not increase incidence of potentially serotonergic AEs; however, phentermine twice daily increased discontinuation compared to both lorcaserin alone and lorcaserin plus phentermine once daily." | 5.24 | Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study. ( Aronne, LJ; Fain, R; Fujioka, K; Garvey, WT; Greenway, FL; Pilson, R; Smith, SR; Zhou, S, 2017) |
| "In a 12-week randomized, double-blind, placebo-controlled clinical trial, 77 adults with obesity received either phentermine or placebo." | 5.22 | Effects of a meal replacement system alone or in combination with phentermine on weight loss and food cravings. ( Aréchiga, AL; Bellinger, DL; Berk, LS; Daher, NS; Davis, WL; Hermé, AC; Moldovan, CP; Peters, WR; Schneider, LE; Weldon, AJ, 2016) |
| "Phentermine is thought to cause weight loss through a reduction in hunger." | 5.22 | Greater hunger and less restraint predict weight loss success with phentermine treatment. ( Bechtell, JL; Cornier, MA; Eckel, RH; Ferland, A; Mcnair, B; Thomas, EA, 2016) |
| " Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has previously shown significant weight loss compared with placebo in a 56-wk study in overweight and obese subjects with ≥2 weight-related comorbidities." | 5.16 | Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. ( Allison, DB; Bowden, CH; Day, WW; Gadde, KM; Garvey, WT; Look, M; Peterson, CA; Ryan, DH; Schwiers, M, 2012) |
| "A 56-week randomized controlled trial was conducted to evaluate safety and efficacy of a controlled-release combination of phentermine and topiramate (PHEN/TPM CR) for weight loss (WL) and metabolic improvements." | 5.16 | Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). ( Allison, DB; Day, WW; Gadde, KM; Garvey, WT; Najarian, T; Peterson, CA; Schwiers, ML; Tam, PY; Troupin, B, 2012) |
| " We therefore assessed the efficacy and safety of two doses of phentermine plus topiramate controlled-release combination as an adjunct to diet and lifestyle modification for weight loss and metabolic risk reduction in individuals who were overweight and obese, with two or more risk factors." | 5.15 | Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. ( Allison, DB; Day, WW; Gadde, KM; Peterson, CA; Ryan, DH; Schwiers, ML; Troupin, B, 2011) |
| "To evaluate the efficacy and safety of a newly developed formulation of phentermine diffuse-controlled release (DCR) in patients with obesity." | 5.14 | Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity. ( Kang, JG; Kang, JH; Park, CY; Park, SW; Park, YW, 2010) |
| "Phentermine/topiramate has considerable benefit in reducing body weight, and the efficacy was closely related to the dosage." | 5.12 | Efficacy and Safety of Phentermine/Topiramate in Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis. ( Lai, C; Lei, XG; Ruan, JQ; Sun, Z; Yang, X, 2021) |
| "A total of 39 postmenopausal women 40-70 years of age and undergoing hormone replacement therapy participated in a 6-month weight reduction program, which consisted of a low calorie diet (5040 KJ/day) and phentermine hydrochloride therapy." | 5.11 | Beneficial effects of weight loss on plasma apolipoproteins in postmenopausal women. ( Conde-Knape, K; Cordero-Macintyre, ZR; Fernandez, ML; Lohman, TG; Metghalchi, S; Vega-López, S, 2004) |
| "To determine the echocardiographic changes over time of valvular heart lesions in patients who took the weight loss drugs fenfluramine and phentermine." | 5.09 | Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. ( Bailey, KR; Connolly, HM; Grogan, M; Hensrud, DD; Jensen, MD; Miller, FA, 1999) |
| "A partial crossover design was used to study a weight loss treatment consisting of Phentermine hydrochloride (Fastin, SmithKline Beecham Pharmaceuticals, Philadelphia, PA) therapy plus a low energy diet (5040 kJ/d)." | 5.09 | Weight loss is correlated with an improved lipoprotein profile in obese postmenopausal women. ( Cordero-MacIntyre, ZR; Dickinson, B; España, RC; Fernandez, ML; Howell, WH; Lohman, TG; Peters, W; Reid, PM; Rosen, J, 2000) |
| "In the population of patients with obesity and CVD, the medications orlistat, lorcaserin and liraglutide are considered the most appropriate options for their treatment, in terms of safety." | 5.01 | Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options. ( Andrew, CA; Aronne, LJ; Saunders, KH; Shukla, AP, 2019) |
| "In this paper, data on efficacy, tolerability and safety of FDA-approved pharmacotherapies for obesity (orlistat, phentermine/topiramate extended-release, lorcaserin, bupropion sustained release/naltrexone sustained release and liraglutide) are reviewed, focusing on individuals with type 2 diabetes." | 4.98 | Pharmacotherapy for obesity in individuals with type 2 diabetes. ( Aronne, LJ; Chukir, T; Saunders, KH; Shukla, AP, 2018) |
| "This review provides an overview of the current state of drug therapy for obesity, with a focus on four new drug therapies-lorcaserin, phentermine/topiramate, naltrexone/bupropion, and liraglutide 3." | 4.95 | Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice. ( Gadde, KM; Pritham Raj, Y, 2017) |
| " Phentermine/topiramate ER appeared to have the best overall average weight loss from baseline as well as highest percentages of patients achieving both ≥5% and ≥10% weight loss benchmarks, followed second by naltrexone/bupropion, and then liraglutide, with lorcaserin showing the lowest rates." | 4.93 | A Comparison of New Pharmacological Agents for the Treatment of Obesity. ( Megyeri, J; Nuffer, W; Trujillo, JM, 2016) |
| "Randomized clinical trials conducted among overweight and obese adults treated with US Food and Drug Administration-approved long-term weight loss agents (orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, or liraglutide) for at least 1 year compared with another active agent or placebo." | 4.93 | Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. ( Camilleri, M; Chandar, AK; Dulai, PS; Khera, R; Loomba, R; Murad, MH; Prokop, LJ; Singh, S; Wang, Z, 2016) |
| "A short overview of new drugs approved for the treatment of obesity (lorcaserin, phentermine/topiramate combination) as well as those with a perspective for approval as antiobesity drugs (cetilistat, naltrexone/bupropion combination, liraglutide) is presented." | 4.90 | Overview of new antiobesity drugs. ( Hainer, V, 2014) |
| " Phentermine and topiramate extended-release (phentermine/topiramate ER) has recently been approved in the USA for chronic weight management in obese adults and overweight adults with weight-related co-morbidities in conjunction with a reduced-calorie diet and increased physical activity." | 4.89 | Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. ( Garvey, WT, 2013) |
| " Phentermine is a noradrenergic sympathomimetic amine approved for short-term treatment of obesity." | 4.86 | Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. ( Bays, H, 2010) |
| " Food and Drug Administration has approved three weight loss agents: sibutramine, orlistat, and phentermine." | 4.83 | Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors. ( Pi-Sunyer, FX, 2006) |
| " The USA, the European Union and Norway have approved orlistat, a pancreatic lipase inhibitor for weight reduction for up to two years." | 4.80 | [The obesity epidemics--do diet pills have a place in the treatment?]. ( Birkeland, KI; Tonstad, S, 2000) |
| " Food and Drug Administration approved phentermine-topiramate for obesity in 2012 and required a Risk Evaluation and Mitigation Strategy (REMS) to prevent prenatal exposure." | 4.31 | Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy. ( Brown, JD; Donahoo, WT; Hampp, C; Sarayani, A; Winterstein, AG, 2023) |
| " The objectives of our study are to describe weight loss, pregnancy rates, and live birth rates after short-term phentermine use in women with obesity and infertility." | 3.96 | A Retrospective Study Examining Phentermine on Preconception Weight Loss and Pregnancy Outcomes. ( Chang, JJ; Kim, SH; Lathi, RB, 2020) |
| "Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, and phentermine, a psychostimulant structurally related to amphetamine, are drugs approved for the treatment of obesity and hyperphagia." | 3.91 | Determining the Effects of Combined Liraglutide and Phentermine on Metabolic Parameters, Blood Pressure, and Heart Rate in Lean and Obese Male Mice. ( Buch-Rasmussen, AS; Cowley, MA; Grove, KL; Kelly, LE; Koegler, FH; Pryor, JT; Simonds, SE, 2019) |
| "The aim of this work was to study weight loss and risk of cardiovascular disease (CVD) or death associated with longer-term phentermine use." | 3.91 | Safety and Effectiveness of Longer-Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort. ( Ard, J; Arterburn, DE; Barton, L; Bessesen, DH; Daley, MF; Desai, J; Fischer, H; Fitzpatrick, SL; Horberg, M; Koebnick, C; Lewis, KH; Oshiro, C; Yamamoto, A; Young, DR, 2019) |
| " Patients receiving phentermine-topiramate had a greater proportion of weight loss after at least 20 weeks compared with those solely enrolled in the VA's MOVE! weight-management program." | 3.88 | Observational Comparative Effectiveness of Pharmaceutical Treatments for Obesity within the Veterans Health Administration. ( Grabarczyk, TR, 2018) |
| "We pooled data from 3,040 overweight and obese participants in three randomized controlled trials-CONQUER, EQUIP, and SEQUEL-assessing efficacy and safety of phentermine/topiramate extended release (ER) for weight loss." | 3.85 | Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release. ( Garvey, WT; Guo, F, 2017) |
| "Phentermine and phentermine-topirimate in addition to diet and exercise appear to be viable options for weight loss in post-RYGB and LAGB patients who experience WR or WLP." | 3.83 | Pharmacotherapy in Conjunction with a Diet and Exercise Program for the Treatment of Weight Recidivism or Weight Loss Plateau Post-bariatric Surgery: a Retrospective Review. ( Chaudhry, UI; Durkin, N; Foreman, KS; Mikami, DJ; Needleman, BJ; Noria, SF; Schwartz, J; Suzo, A; Tychonievich, K; Wehr, AM, 2016) |
| "The recent approval of liraglutide, lorcaserin, naltrexone/bupropion extended-release, and phentermine/topiramate extended-release, brings the number of medications for long-term weight loss to 5 (including orlistat)." | 3.83 | Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management. ( Braverman-Panza, J; Fujioka, K, 2016) |
| "Phentermine/topiramate combination therapy resulted in significant weight loss and improvements in cardiometabolic risk factors in patients with obesity/overweight in two published 56-week randomized, placebo-controlled trials (EQUIP and CONQUER)." | 3.83 | Health-related quality of life in two randomized controlled trials of phentermine/topiramate for obesity: What mediates improvement? ( Crosby, RD; Gadde, KM; Kolotkin, RL; Peterson, CA, 2016) |
| "Phase 3 clinical trial results reveal that Qsymia is a clinically effective long-term treatment for obesity, but whether this treatment is cost-effective compared to a diet and lifestyle intervention has yet to be explored." | 3.81 | Cost-Effectiveness Analysis of Qsymia for Weight Loss. ( Finkelstein, EA; Karnawat, S; Kruger, E, 2015) |
| " Importantly, the appetite suppressant-induced weight loss and locomotion were markedly reduced by intragastric (and intra-NAc shell) infusions of dopamine antagonists SCH-23390 (D1 receptor) or raclopride (D2 receptor)." | 3.81 | D1 and D2 antagonists reverse the effects of appetite suppressants on weight loss, food intake, locomotion, and rebalance spiking inhibition in the rat NAc shell. ( Elias, D; Gutierrez, R; Kalyanasundar, B; Luna, A; Moreno, MG; Perez, CI; Simon, SA; Solorio, J, 2015) |
| "To investigate the safety, tolerability and efficacy of combination phentermine and topiramate therapy for maintenance of weight loss." | 3.80 | Combination phentermine and topiramate for weight maintenance: the first Australian experience. ( Haywood, CJ; Houlihan, CA; Lee, FT; Neoh, SL; Proietto, J; Sumithran, P, 2014) |
| "Phentermine abuse or psychological dependence (addiction) does not occur in patients treated with phentermine for obesity." | 3.80 | Addiction potential of phentermine prescribed during long-term treatment of obesity. ( De Marco, DG; Greenway, FL; Haggard, M; Hendricks, EJ; Hendricks, MJ; Istratiy, Y; Mitchell, CL; Schmidt, SL; Souter, S; Srisurapanont, M, 2014) |
| "To determine the impact of FDA safety communications regarding the weight loss medications sibutramine and orlistat." | 3.80 | Time series analyses of the effect of FDA communications on use of prescription weight loss medications. ( Block, JP; Brennan, TA; Carpenter, DP; Choudhry, NK; Fischer, MA; Matlin, OS; Shrank, WH; Tong, AY, 2014) |
| "In 2012, the US Food and Drug Administration approved 2 drugs for long-term weight loss: lorcaserin hydrochloride (Belviq; Eisai Inc) and phentermine-topiramate (Qysmia; Vivus Inc)." | 3.80 | The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings? ( Schwartz, LM; Woloshin, S, 2014) |
| " Phentermine is widely used in many countries despite its multiple adverse effects and lack of proven efficacy in preventing complications of obesity." | 3.78 | Phentermine: an appetite-suppressant amphetamine classified as a narcotic in France. Is a combination with topiramate on the horizon? ( , 2012) |
| "A 35-year-old woman taking phentermine for weight loss presented with altered mental status and 2 witnessed generalized seizures." | 3.77 | Posterior reversible encephalopathy syndrome in the context of phentermine use resulting in intracranial hemorrhage. ( Singh, H; Verro, P; Wong, VS, 2011) |
| "Qnexa (VI-0521) is an investigational fixed-dose combination drug of phentermine and topiramate currently in Phase III clinical trials for the treatment of obesity." | 3.77 | ACS chemical neuroscience molecule spotlight on Qnexa. ( Mercer, SL, 2011) |
| "There is a perception that phentermine pharmacotherapy for obesity increases blood pressure and heart rate (HR), exposing treated patients to increased cardiovascular risk." | 3.77 | Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. ( Greenway, FL; Gupta, AK; Hendricks, EJ; Westman, EC, 2011) |
| " We present the unique case of a Choctaw lady with morbid obesity who has shown a profound response to pharmacotherapy with phentermine." | 3.75 | A case of profound weight loss secondary to use of phentermine. ( Koch, CA; McDonald, A; Melcescu, E; Uwaifo, GI, 2009) |
| "This is a report of health-related quality of life (HRQOL) changes in obese patients completing at least 1 year of outpatient treatment in a weight reduction program combining phentermine-fenfluramine and dietary counseling." | 3.71 | The relationship between health-related quality of life and weight loss. ( Crosby, RD; Hartley, GG; Kolotkin, RL; Nicol, S; Williams, GR, 2001) |
| "To assess weight loss, as well as the prevalence of valvular heart disease, in 21 obese women who completed 2 years of treatment by fenfluramine and phentermine (fen-phen) in June 1997." | 3.70 | The fen-phen finale: a study of weight loss and valvular heart disease. ( Aber, JL; Berkowitz, RI; Foster, GD; Silvestry, F; St John Sutton, MG; Stunkard, AJ; Vogt, RA; Wadden, TA, 1998) |
| "Phentermine and fenfluramine are widely used in the treatment of obesity." | 3.70 | Lower dosages of phentermine-fenfluramine given in the afternoon: five cases with significant weight loss. ( Katz, DA; Maloney, MJ; McConville, BJ; Sutkamp, JC, 1999) |
| "22 severe binge eaters, 17 moderate binge eaters, and 16 non-binge eaters received phentermine resin 15mg/day and dl-fenfluramine 20mg three times daily over a 6 month period for weight loss." | 3.70 | Beneficial effects of pharmacotherapy on weight loss, depressive symptoms, and eating patterns in obese binge eaters and non-binge eaters. ( Alger, SA; Cerulli, J; Fein, S; Howard, L; Malone, M, 1999) |
| "To evaluate, in compliant patients, the pharmaceutical costs of treating obesity with fenfluramine/mazindol, fenfluramine/phentermine, caffeine/ephedrine, or mazindol relative to the pharmaceutical costs of treating obesity-related comorbid conditions and reducing cardiovascular risk." | 3.70 | Pharmaceutical cost savings of treating obesity with weight loss medications. ( Bray, GA; Greenway, FL; Rood, JC; Ryan, DH; Smith, SR; Tucker, EW, 1999) |
| "Overall, large weight loss has a major beneficial impact on overweight- and obesity-related complications." | 2.82 | Benefits of weight loss of 10% or more in patients with overweight or obesity: A review. ( Morton, J; Tahrani, AA, 2022) |
| "Treatment algorithms for type 2 diabetes recommend weight loss for disease management." | 2.79 | Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. ( Bohannon, NJ; Dvorak, RV; Garvey, WT; Kushner, RF; Rueger, M; Ryan, DH; Troupin, B, 2014) |
| "Obesity is highly prevalent worldwide, including among people with chronic kidney disease (CKD)." | 2.72 | Intensive management of obesity in people with severe chronic kidney disease: A review. ( Harb, H; Nolan, BJ; Song, R; Sumithran, P, 2021) |
| " Dry mouth and insomnia were the only statistically significant adverse events that occurred more frequently in phentermine group." | 2.72 | Effects on weight reduction and safety of short-term phentermine administration in Korean obese people. ( Cho, HJ; Kang, HC; Kim, KK; Lee, KR; Youn, BB, 2006) |
| "Hypertension is a major risk factor for cardiovascular and renal diseases in the United States and worldwide." | 2.72 | Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association. ( Ard, JD; Cohen, JB; Egan, BM; Hall, JE; Hall, ME; Lavie, CJ; Ma, J; Ndumele, CE; Schauer, PR; Shimbo, D, 2021) |
| " However, they are costly and may have adverse effects in some individuals." | 2.72 | Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? ( Lee, SY; Tak, YJ, 2021) |
| "Most individuals with type 2 diabetes are overweight, and weight loss for them is an important therapeutic objective." | 2.69 | Pharmacologic induction of weight loss to treat type 2 diabetes. ( Bantle, JP; Kwong, CA; Raatz, SK; Redmon, JB; Swanson, JE; Thomas, W, 1999) |
| "Initial weight loss has been used as a predictor of long-term response to obesity drugs." | 2.69 | Initial weight loss as a predictor of response to obesity drugs. ( Atkinson, RL; Blank, RC; Dhurandhar, NV; Schumacher, D, 1999) |
| " Dosing changes were based on an algorithm that aimed to achieve 120% of ideal body weight (IBW) while minimizing adverse effects." | 2.67 | Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine. ( Moscucci, M; Schuster, B; Stein, EC; Sundaresan, PR; Weintraub, M, 1992) |
| " Thus, if following the appropriate guidelines according to package labels, the practitioner can feel safe in prescribing these medications." | 2.52 | Safety and tolerability of medications approved for chronic weight management. ( Fujioka, K, 2015) |
| "The treatment of obesity is often met with a myriad of challenges in the primary care setting." | 2.50 | Combination phentermine/topiramate for obesity treatment in primary care: a review. ( Gadde, KM; Xiong, GL, 2014) |
| " Cardiovascular data associated with long-term use of phentermine and topiramate extended-release indicate that this combination may be a safe and effective option for reducing weight in overweight/obese patients at low-to-intermediate cardiovascular risk." | 2.50 | Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. ( Astrup, A; Day, WW; Engeli, S; Finer, N; Jordan, J; Narkiewicz, K, 2014) |
| " At present there are three drugs (orlistat, phentermine/topiramate and lorcaserin) approved for long-term use and four sympathomimetic drugs approved by the US FDA for short-term treatment of obesity." | 2.50 | Medical treatment of obesity: the past, the present and the future. ( Bray, GA, 2014) |
| "Qsymia is a combination of phentermine and topiramate used for obesity treatment." | 2.49 | Phentermine and topiramate extended-release for the obesity: new kids on the block. ( Kallikazaros, I; Kallistratos, MS; Katsi, V; Makris, T; Manolis, AJ; Marketou, M; Tousoulis, D; Vardas, P, 2013) |
| "The prevalence of obesity is rising worldwide, with the U." | 2.48 | Recent advancements in drug treatment of obesity. ( Carter, R; Mouralidarane, A; Oben, J; Ray, S; Soeda, J, 2012) |
| "Obesity is a chronic disease requiring a similar long term approach to management as that of other chronic conditions." | 2.43 | Weight loss medications--where do they fit in? ( Dixon, JB, 2006) |
| "Obesity is a major health concern which must be treated." | 2.40 | Pharmacological approaches to intervention. ( Guy-Grand, B, 1997) |
| "Obesity is a chronic disease, which similar to diabetes and hypertension, requires long-term treatment." | 2.40 | Obesity. ( Aronne, LJ, 1998) |
| "0001), with similar serious adverse event rates (2." | 1.91 | Combining transoral outlet reduction with pharmacotherapy yields similar 1-year efficacy with improved safety compared with surgical revision for weight regain after Roux-en-Y gastric bypass (with videos). ( Jirapinyo, P; Thompson, CC, 2023) |
| "Nearly 90% of individuals with type 2 diabetes mellitus (T2DM) are either overweight or obese, placing them at high risk of microvascular and macrovascular complications." | 1.72 | Prevalence of Antiobesity Treatment and Weight-Inducing Antihyperglycemic Agents Among Patients With Type 2 Diabetes in the United States. ( Kaur, N; Levin, A; Mainoo, NK; Perez, A, 2022) |
| "Obesity is a chronic disease universally defined as an excess of adipose tissue resulting in body mass index (BMI) > 30." | 1.46 | Obesity Epidemic: Pharmaceutical Weight Loss. ( Curry, SA, 2017) |
| "Phentermine use was associated with a greater percent change in BMI at 1 month (-1." | 1.46 | Effect of phentermine on weight reduction in a pediatric weight management clinic. ( Fox, CK; Gross, A; Kaizer, A; Kelly, AS; Rudser, KD; Ryder, JR, 2017) |
| " Off-label prescribing includes using medications for unapproved indications; using a drug outside of the recommended dosage range or duration of use; using a drug in certain unapproved patient populations, such as those defined by age, sex, or particular clinical parameters; or intentionally using a medication in a patient who has a known contraindication." | 1.38 | Off-label medication use. ( Howland, RH, 2012) |
| "Type 2 diabetes mellitus is one of the significant comorbidities of obesity." | 1.37 | Obesity and type 2 diabetes mellitus in South Dakota: focused insight into prevalence, physiology and treatment. ( Eid, WE, 2011) |
| "To evaluate the long-term impact of Medifast meal-replacement supplements (MMRS) combined with appetite suppressant medication (ASM) among participants who received 52 weeks of treatment." | 1.35 | Effectiveness of Medifast supplements combined with obesity pharmacotherapy: a clinical program evaluation. ( DiBartolomeo, JJ; Foreyt, JP; Haddock, CK; Poston, WS; Warner, PO, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.72) | 18.7374 |
| 1990's | 22 (15.94) | 18.2507 |
| 2000's | 15 (10.87) | 29.6817 |
| 2010's | 77 (55.80) | 24.3611 |
| 2020's | 23 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hall, ME | 1 |
| Cohen, JB | 1 |
| Ard, JD | 1 |
| Egan, BM | 1 |
| Hall, JE | 1 |
| Lavie, CJ | 1 |
| Ma, J | 1 |
| Ndumele, CE | 1 |
| Schauer, PR | 1 |
| Shimbo, D | 1 |
| Ryan, DH | 6 |
| Calderon, G | 1 |
| Gonzalez-Izundegui, D | 1 |
| Shan, KL | 1 |
| Garcia-Valencia, OA | 1 |
| Cifuentes, L | 1 |
| Campos, A | 1 |
| Collazo-Clavell, ML | 1 |
| Shah, M | 1 |
| Hurley, DL | 1 |
| Abu Lebdeh, HS | 1 |
| Sharma, M | 1 |
| Schmitz, K | 1 |
| Clark, MM | 1 |
| Grothe, K | 1 |
| Mundi, MS | 1 |
| Camilleri, M | 2 |
| Abu Dayyeh, BK | 1 |
| Hurtado Andrade, MD | 1 |
| Mokadem, MA | 1 |
| Acosta, A | 1 |
| Levin, A | 1 |
| Kaur, N | 1 |
| Mainoo, NK | 1 |
| Perez, A | 1 |
| Kwon, YJ | 1 |
| Kwon, GE | 1 |
| Lee, HS | 1 |
| Choi, MH | 1 |
| Lee, JW | 1 |
| Tahrani, AA | 1 |
| Morton, J | 1 |
| Nolan, BJ | 2 |
| Proietto, J | 2 |
| Sumithran, P | 3 |
| Dhillon, S | 1 |
| Griebeler, ML | 1 |
| Butsch, WS | 1 |
| Rodriguez, P | 1 |
| Lomeli, L | 1 |
| Kampert, M | 1 |
| Makin, V | 1 |
| Alwahab, UA | 1 |
| Borukh, E | 1 |
| Daigle, E | 1 |
| Bena, J | 1 |
| Pantalone, KM | 1 |
| Burguera, B | 1 |
| Ali Ibrahim, AI | 1 |
| Mendoza, B | 1 |
| Stanford, FC | 1 |
| Malhotra, S | 1 |
| Sarayani, A | 1 |
| Donahoo, WT | 1 |
| Hampp, C | 1 |
| Brown, JD | 1 |
| Winterstein, AG | 1 |
| Jirapinyo, P | 1 |
| Thompson, CC | 1 |
| Bourke, S | 1 |
| Morton, JM | 1 |
| Williams, P | 1 |
| Son, JW | 1 |
| Kim, S | 1 |
| Tak, YJ | 1 |
| Lee, SY | 1 |
| Chang, JJ | 1 |
| Lathi, RB | 1 |
| Kim, SH | 1 |
| Redmond, IP | 1 |
| Shukla, AP | 4 |
| Aronne, LJ | 9 |
| Lei, XG | 1 |
| Ruan, JQ | 1 |
| Lai, C | 1 |
| Sun, Z | 1 |
| Yang, X | 1 |
| Song, R | 1 |
| Harb, H | 1 |
| Elkind-Hirsch, KE | 1 |
| Chappell, N | 1 |
| Seidemann, E | 1 |
| Storment, J | 1 |
| Bellanger, D | 1 |
| Patel, M | 1 |
| Daboul, J | 1 |
| Iftikhar, S | 1 |
| Burmeister, C | 1 |
| Ambati, A | 1 |
| Moukarbel, G | 1 |
| Assaly, R | 1 |
| Ahmad, NN | 1 |
| Robinson, S | 1 |
| Kennedy-Martin, T | 1 |
| Poon, JL | 1 |
| Kan, H | 1 |
| Gadde, KM | 7 |
| Pritham Raj, Y | 1 |
| Smith, SR | 3 |
| Garvey, WT | 6 |
| Greenway, FL | 5 |
| Zhou, S | 1 |
| Fain, R | 1 |
| Pilson, R | 1 |
| Fujioka, K | 4 |
| Guo, F | 1 |
| Grabarczyk, TR | 1 |
| Chukir, T | 1 |
| Saunders, KH | 2 |
| Ritchey, ME | 1 |
| Harding, A | 1 |
| Hunter, S | 1 |
| Peterson, C | 2 |
| Sager, PT | 1 |
| Kowey, PR | 1 |
| Nguyen, L | 1 |
| Thomas, S | 1 |
| Cainzos-Achirica, M | 1 |
| Rothman, KJ | 1 |
| Andrews, EB | 1 |
| Anthony, MS | 1 |
| Andrew, CA | 1 |
| Simonds, SE | 1 |
| Pryor, JT | 1 |
| Koegler, FH | 1 |
| Buch-Rasmussen, AS | 1 |
| Kelly, LE | 1 |
| Grove, KL | 1 |
| Cowley, MA | 1 |
| Lewis, KH | 2 |
| Fischer, H | 2 |
| Ard, J | 2 |
| Barton, L | 1 |
| Bessesen, DH | 1 |
| Daley, MF | 1 |
| Desai, J | 2 |
| Fitzpatrick, SL | 1 |
| Horberg, M | 2 |
| Koebnick, C | 2 |
| Oshiro, C | 2 |
| Yamamoto, A | 1 |
| Young, DR | 2 |
| Arterburn, DE | 2 |
| Tronieri, JS | 1 |
| Wadden, TA | 6 |
| Walsh, OA | 1 |
| Berkowitz, RI | 5 |
| Alamuddin, N | 1 |
| Gruber, K | 1 |
| Leonard, S | 1 |
| Chao, AM | 1 |
| Murali, S | 1 |
| Bessesen, D | 1 |
| Daley, M | 1 |
| Fitzpatrick, S | 1 |
| Katsi, V | 1 |
| Marketou, M | 1 |
| Kallistratos, MS | 1 |
| Tousoulis, D | 1 |
| Makris, T | 1 |
| Manolis, AJ | 1 |
| Vardas, P | 1 |
| Kallikazaros, I | 1 |
| Murfin, M | 1 |
| Hendricks, EJ | 4 |
| Srisurapanont, M | 1 |
| Schmidt, SL | 1 |
| Haggard, M | 1 |
| Souter, S | 1 |
| Mitchell, CL | 1 |
| De Marco, DG | 1 |
| Hendricks, MJ | 1 |
| Istratiy, Y | 1 |
| Block, JP | 1 |
| Choudhry, NK | 1 |
| Carpenter, DP | 1 |
| Fischer, MA | 1 |
| Brennan, TA | 1 |
| Tong, AY | 1 |
| Matlin, OS | 1 |
| Shrank, WH | 1 |
| Kelly, EM | 1 |
| Tungol, AA | 1 |
| Wesolowicz, LA | 1 |
| Winslow, D | 1 |
| Odeh, S | 1 |
| Weissman-Miller, D | 1 |
| Miras, AD | 1 |
| le Roux, CW | 1 |
| Kushner, RF | 2 |
| Apovian, CM | 3 |
| Woloshin, S | 2 |
| Schwartz, LM | 2 |
| Jordan, J | 1 |
| Astrup, A | 1 |
| Engeli, S | 1 |
| Narkiewicz, K | 1 |
| Day, WW | 4 |
| Finer, N | 1 |
| Xiong, GL | 1 |
| Finkelstein, EA | 1 |
| Kruger, E | 1 |
| Karnawat, S | 1 |
| Kyle, TK | 1 |
| Nadglowski, J | 1 |
| Hainer, V | 1 |
| Kalarchian, M | 1 |
| Turk, M | 1 |
| Elliott, J | 1 |
| Gourash, W | 1 |
| Neoh, SL | 1 |
| Haywood, CJ | 1 |
| Houlihan, CA | 1 |
| Lee, FT | 1 |
| Bray, GA | 3 |
| Bohannon, NJ | 1 |
| Rueger, M | 1 |
| Dvorak, RV | 1 |
| Troupin, B | 3 |
| Citrome, L | 1 |
| Kumar, RB | 1 |
| Alfaris, N | 1 |
| Minnick, AM | 1 |
| Hopkins, CM | 1 |
| Kalyanasundar, B | 1 |
| Perez, CI | 1 |
| Luna, A | 1 |
| Solorio, J | 1 |
| Moreno, MG | 1 |
| Elias, D | 1 |
| Simon, SA | 1 |
| Gutierrez, R | 1 |
| Kolotkin, RL | 2 |
| Peterson, CA | 4 |
| Crosby, RD | 2 |
| Thomas, EA | 1 |
| Mcnair, B | 1 |
| Bechtell, JL | 1 |
| Ferland, A | 1 |
| Cornier, MA | 1 |
| Eckel, RH | 1 |
| Schwartz, J | 1 |
| Chaudhry, UI | 1 |
| Suzo, A | 1 |
| Durkin, N | 1 |
| Wehr, AM | 1 |
| Foreman, KS | 1 |
| Tychonievich, K | 1 |
| Mikami, DJ | 1 |
| Needleman, BJ | 1 |
| Noria, SF | 1 |
| Nuffer, W | 1 |
| Trujillo, JM | 1 |
| Megyeri, J | 1 |
| Siebenhofer, A | 1 |
| Jeitler, K | 1 |
| Horvath, K | 1 |
| Berghold, A | 1 |
| Posch, N | 1 |
| Meschik, J | 1 |
| Semlitsch, T | 1 |
| Khera, R | 1 |
| Murad, MH | 1 |
| Chandar, AK | 1 |
| Dulai, PS | 1 |
| Wang, Z | 1 |
| Prokop, LJ | 1 |
| Loomba, R | 1 |
| Singh, S | 1 |
| Braverman-Panza, J | 1 |
| Thomas, CE | 1 |
| Mauer, EA | 1 |
| Rathi, S | 1 |
| Moldovan, CP | 1 |
| Weldon, AJ | 1 |
| Daher, NS | 1 |
| Schneider, LE | 1 |
| Bellinger, DL | 1 |
| Berk, LS | 1 |
| Hermé, AC | 1 |
| Aréchiga, AL | 1 |
| Davis, WL | 1 |
| Peters, WR | 1 |
| Ryder, JR | 1 |
| Kaizer, A | 1 |
| Rudser, KD | 1 |
| Gross, A | 1 |
| Kelly, AS | 1 |
| Fox, CK | 1 |
| Curry, SA | 1 |
| Haddock, CK | 1 |
| Poston, WS | 1 |
| Foreyt, JP | 1 |
| DiBartolomeo, JJ | 1 |
| Warner, PO | 1 |
| Rothman, RB | 2 |
| McPhilomy, E | 1 |
| Halseth, AE | 1 |
| Burns, CM | 1 |
| Miller, S | 1 |
| Shen, LZ | 1 |
| Kaplan, LM | 1 |
| Bays, H | 1 |
| Uwaifo, GI | 1 |
| Melcescu, E | 1 |
| McDonald, A | 1 |
| Koch, CA | 1 |
| Kang, JG | 1 |
| Park, CY | 1 |
| Kang, JH | 1 |
| Park, YW | 1 |
| Park, SW | 1 |
| Wong, VS | 1 |
| Singh, H | 1 |
| Verro, P | 1 |
| Delaet, D | 1 |
| Schauer, D | 1 |
| Allison, DB | 3 |
| Schwiers, ML | 2 |
| Shah, K | 1 |
| Villareal, DT | 1 |
| Westman, EC | 1 |
| Gupta, AK | 1 |
| Wilbert, B | 1 |
| Mohundro, BL | 1 |
| Shaw, V | 1 |
| Andres, A | 1 |
| Eid, WE | 1 |
| Malgarini, RB | 1 |
| Pimpinella, G | 1 |
| Cohen, PA | 1 |
| Najarian, T | 1 |
| Tam, PY | 1 |
| Look, M | 1 |
| Schwiers, M | 1 |
| Bowden, CH | 1 |
| Hiatt, WR | 1 |
| Thomas, A | 1 |
| Goldfine, AB | 1 |
| Gokce, N | 1 |
| Mercer, SL | 1 |
| Bello, NT | 1 |
| Campbell, SC | 1 |
| Howland, RH | 1 |
| Colman, E | 1 |
| Golden, J | 1 |
| Roberts, M | 1 |
| Egan, A | 1 |
| Weaver, J | 1 |
| Rosebraugh, C | 1 |
| Carter, R | 1 |
| Mouralidarane, A | 1 |
| Ray, S | 1 |
| Soeda, J | 1 |
| Oben, J | 1 |
| Gura, T | 1 |
| Munro, JF | 1 |
| MacCuish, AC | 1 |
| Wilson, EM | 1 |
| Duncan, LJ | 1 |
| Fernandez, ML | 2 |
| Metghalchi, S | 1 |
| Vega-López, S | 1 |
| Conde-Knape, K | 1 |
| Lohman, TG | 3 |
| Cordero-Macintyre, ZR | 3 |
| Dixon, JB | 1 |
| Pi-Sunyer, FX | 1 |
| Kim, KK | 1 |
| Cho, HJ | 1 |
| Kang, HC | 1 |
| Youn, BB | 1 |
| Lee, KR | 1 |
| Whigham, LD | 1 |
| Dhurandhar, NV | 2 |
| Rahko, PS | 1 |
| Atkinson, RL | 2 |
| Khan, M | 1 |
| Lum, CT | 1 |
| Rao, V | 1 |
| Brune, DB | 1 |
| Guy-Grand, B | 1 |
| Vogt, RA | 2 |
| Steen, SN | 1 |
| Stunkard, AJ | 2 |
| Foster, GD | 3 |
| Garrett, SD | 1 |
| Cupp, MJ | 1 |
| Silvestry, F | 1 |
| St John Sutton, MG | 1 |
| Aber, JL | 2 |
| Cowley, G | 1 |
| Springen, K | 1 |
| Katz, DA | 1 |
| Maloney, MJ | 1 |
| Sutkamp, JC | 1 |
| McConville, BJ | 1 |
| Silvestry, FE | 1 |
| Sutton, MG | 1 |
| Redmon, JB | 1 |
| Raatz, SK | 1 |
| Kwong, CA | 1 |
| Swanson, JE | 1 |
| Thomas, W | 1 |
| Bantle, JP | 1 |
| Helmcke, F | 1 |
| Sander, G | 1 |
| Volaufova, J | 1 |
| Greenway, F | 1 |
| Subramaniam, P | 1 |
| Glancy, DL | 1 |
| Alger, SA | 1 |
| Malone, M | 1 |
| Cerulli, J | 1 |
| Fein, S | 1 |
| Howard, L | 1 |
| Rood, JC | 1 |
| Tucker, EW | 1 |
| Hensrud, DD | 1 |
| Connolly, HM | 1 |
| Grogan, M | 1 |
| Miller, FA | 1 |
| Bailey, KR | 1 |
| Jensen, MD | 1 |
| Blank, RC | 1 |
| Schumacher, D | 1 |
| Rosen, J | 1 |
| Peters, W | 2 |
| España, RC | 2 |
| Dickinson, B | 1 |
| Reid, PM | 1 |
| Howell, WH | 2 |
| Libanati, CR | 1 |
| Tonstad, S | 1 |
| Birkeland, KI | 1 |
| Williams, GR | 1 |
| Hartley, GG | 1 |
| Nicol, S | 1 |
| Francis, GS | 1 |
| Weintraub, M | 5 |
| Sundaresan, PR | 4 |
| Madan, M | 2 |
| Schuster, B | 3 |
| Balder, A | 2 |
| Lasagna, L | 1 |
| Cox, C | 2 |
| Ginsberg, G | 1 |
| Stein, EC | 2 |
| Byrne, L | 1 |
| Moscucci, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Use of a Virtual Weight Management Program for Prescription of Phentermine in Patients With Overweight or Obesity Compared to Standard Face to Face Visits[NCT04614545] | Phase 4 | 70 participants (Actual) | Interventional | 2021-01-01 | Completed | ||
| Comparison of Dapagliflozin (DAPA) and Once-weekly Exenatide (EQW), Co-administered or Alone, DAPA/ Glucophage (DAPA/MET ER) and Phentermine/Topiramate (PHEN/TPM) ER on Metabolic Profiles and Body Composition in Obese PCOS Women[NCT02635386] | Phase 3 | 119 participants (Actual) | Interventional | 2016-03-22 | Completed | ||
| A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Ob[NCT01987427] | Phase 4 | 344 participants (Actual) | Interventional | 2013-10-30 | Completed | ||
| A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Extension Study (From Study OB-303 [NCT00553787]) to Determine the Safety and Efficacy Of VI-0521 for the Long-Term Treatment Of Obesity in Adults With Obesity-Related Co-Morbid Conditions.[NCT00796367] | Phase 3 | 676 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| A Phase III Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in an Adult Population With BMI ≥ 35[NCT00554216] | Phase 3 | 1,267 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| A Phase III Randomized, Double-Blind, Placebo Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions[NCT00553787] | Phase 3 | 2,487 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Medications After Adolescent Bariatric Surgery Protocol for Inadequate Weight Loss Following Sleeve Gastrectomy in Adolescents and Young Adults: A Pilot Feasibility Study[NCT04572217] | Phase 2 | 0 participants (Actual) | Interventional | 2022-06-30 | Withdrawn (stopped due to No available funding) | ||
| Moxibustion Combined With Characteristic Lifestyle Intervention of Traditional Chinese Medicine in the Treatment of Abdominal Obesity: A Study Protocol for a Randomized Controlled Trial[NCT04501198] | 150 participants (Anticipated) | Interventional | 2020-09-30 | Not yet recruiting | |||
| The Efficacy and Safety of Electro-acupuncture for Abdominal Obesity: Original Study for a Multicenter, Randomized, Sham-controlled Trial[NCT04957134] | 66 participants (Actual) | Interventional | 2021-07-22 | Completed | |||
| Combining Lifestyle Modification and Liraglutide to Improve Weight Loss and Health Outcomes[NCT02911818] | Phase 4 | 150 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| A Randomized, Double Blind Multicenter Study to Evaluate the Long-term Safety and Efficacy of VI-0521 Relative to Placebo in Providing and Maintaining Glycemic Control in Type 2 Diabetic Adults[NCT00600067] | Phase 2 | 130 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Electroacupuncture Combined With Umbilical Moxibustion on Abdominal Obesity of Yang Deficiency: A Study Protocol for a Randomized Controlled Trial[NCT04835181] | 68 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | |||
| Use of the Medifast Meal Replacement Program for Weight Loss in Obese Patients: A Restrospective Chart Review of Three Medifast Weight Control Centers (MWCC)[NCT01662830] | 446 participants (Actual) | Observational | 2010-04-30 | Completed | |||
| Long-term Phentermine Pharmacotherapy: An Investigation for Symptoms of Dependence, Cravings, or Withdrawal[NCT01402674] | 269 participants (Actual) | Interventional | 2011-08-31 | Completed | |||
| Effect of Sulphate-bicarbonate-calcium Water Consumption on the Body Weight and Gut Microbiota Composition in Overweight and Obese Patients Under Low-calorie Diet[NCT02154230] | 0 participants (Actual) | Interventional | 2013-11-30 | Withdrawn (stopped due to failure to enroll) | |||
| [NCT00000506] | Phase 2 | 0 participants | Interventional | 1983-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of patients that took the medication as prescribed (NCT04614545)
Timeframe: 12 weeks
| Intervention | Percentage of pts completed medication (Number) |
|---|---|
| Virtual Visits | 93.3 |
| Face to Face Visits | 83.3 |
Assessed as percentage of patients who completed all visits (NCT04614545)
Timeframe: 12 weeks
| Intervention | Percentage of completed patients (Number) |
|---|---|
| Virtual Visits | 82.9 |
| Face to Face Visits | 62.9 |
The primary endpoint is mean change in body weight (%) from baseline (visit 1) to 12 weeks (visit 4) in body weight. (NCT04614545)
Timeframe: 12 weeks
| Intervention | mean change in body weight (%) (Mean) |
|---|---|
| Virtual Visits | -6.61 |
| Face to Face Visits | -7.68 |
(NCT04614545)
Timeframe: 12 weeks
| Intervention | Percentage of patients on full dose (Number) |
|---|---|
| Virtual Visits | 85.7 |
| Face to Face Visits | 90 |
(NCT04614545)
Timeframe: 12 weeks
| Intervention | Percentage of patients with >5% wt loss (Number) |
|---|---|
| Virtual Visits | 64.7 |
| Face to Face Visits | 70.5 |
Treatment effect on body weight at 24 weeks of treatment (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | kilogram (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 100.4 |
| Dapagliflozin (DAPA) | 102.6 |
| EQW Plus DAPA | 99 |
| Dapagliflozin Plus Glucophage (MET ER) | 101.2 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 97 |
treatment impact on measure of central adiposity as determined by android/gynoid ratio (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | ratio (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 1.07 |
| Dapagliflozin (DAPA) | 1.02 |
| EQW Plus DAPA | 1.04 |
| Dapagliflozin Plus Glucophage (MET ER) | 1.04 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 1.03 |
Treatment efficacy in reducing body mass at 24 weeks of treatment (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | kilogram/meter squared (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 37.3 |
| Dapagliflozin (DAPA) | 37.4 |
| EQW Plus DAPA | 36.7 |
| Dapagliflozin Plus Glucophage (MET ER) | 37 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 35.3 |
Treatment effect on loss of central adiposity after 24 weeks (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | centimeters (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 104 |
| Dapagliflozin (DAPA) | 101 |
| EQW Plus DAPA | 106 |
| Dapagliflozin Plus Glucophage (MET ER) | 101.3 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 97 |
Treatment effect on change in percent body weight from baseline (NCT02635386)
Timeframe: Change from baseline (time 0) to study end (24 weeks)
| Intervention | percentage change in body weight (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 3.8 |
| Dapagliflozin (DAPA) | 1.5 |
| EQW Plus DAPA | 6.9 |
| Dapagliflozin Plus Glucophage (MET ER) | 1.7 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 8.1 |
Treatment effect on insulin secretion from 0 to 30 minutes after glucose load corrected for by fasting insulin sensitivity. A higher score shows improved first phase insulin secretion in response to glucose (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | index score (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 1.03 |
| Dapagliflozin (DAPA) | 0.6 |
| EQW Plus DAPA | 0.91 |
| Dapagliflozin Plus Glucophage (MET ER) | 0.7 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 1.1 |
Treatment effect on blood concentrations of DHEA-S (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mcg/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 165 |
| Dapagliflozin (DAPA) | 187 |
| EQW Plus DAPA | 169 |
| Dapagliflozin Plus Glucophage (MET ER) | 189 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 201 |
Treatment effect on DBP after 24 weeks (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 81 |
| Dapagliflozin (DAPA) | 79.8 |
| EQW Plus DAPA | 76 |
| Dapagliflozin Plus Glucophage (MET ER) | 82 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 83.6 |
Treatment impact on fasting concentration of glucose in the blood (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 91 |
| Dapagliflozin (DAPA) | 93 |
| EQW Plus DAPA | 86.5 |
| Dapagliflozin Plus Glucophage (MET ER) | 89 |
| Phentermine /Topiramate (PHEN/ TPM ER | 91.4 |
Treatment effect on the ratio HOMA-IR which is insulin resistance measure derived from fasting blood glucose and insulin and is calculated by insulin (mU/ml)*glucose (mmol/L)/22,5. The higher thenumber the more insulin resistant. (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | index score (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 3.7 |
| Dapagliflozin (DAPA) | 3.6 |
| EQW Plus DAPA | 2.6 |
| Dapagliflozin Plus Glucophage (MET ER) | 3.3 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 3.4 |
Treatment effect on FAI calculated from total testosterone divided by sex hormone binding globulin (SHBG) levels. A higher score indicates a worse outcome. (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | index score (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 5.3 |
| Dapagliflozin (DAPA) | 4.7 |
| EQW Plus DAPA | 5.2 |
| Dapagliflozin Plus Glucophage (MET ER) | 5.7 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 5 |
The SI IOGTT is a measure of peripheral insulin sensitivity derived from the values of Insulin (microunits per milliliter) and Glucose (milligrams per deciliter) obtained from the OGTT and the corresponding fasting values. SI (OGTT) = 10,000/ [(G fasting x I fasting) x (G OGTTmean x I OGTTmean)], where fasting glucose and insulin data are taken from time 0 of the OGTT and mean data represent the average glucose and insulin values obtained during the entire OGTT. The square root is used to correct for nonlinear distribution of insulin, and 10,000 is a scaling factor in the equation. The higher value, the more sensitive to insulin. (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | index score (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 3.1 |
| Dapagliflozin (DAPA) | 3.6 |
| EQW Plus DAPA | 3.9 |
| Dapagliflozin Plus Glucophage (MET ER) | 4.8 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 4.7 |
Treatment effect on MBG measured during the oral glucose tolerance test (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 118 |
| Dapagliflozin (DAPA) | 126.4 |
| EQW Plus DAPA | 112 |
| Dapagliflozin Plus Glucophage (MET ER) | 119 |
| Phentermine /Topiramate (PHEN/ TPM ER | 113 |
An estimation of β-cell compensatory function, the insulin secretion-sensitivity index (IS-SI) will be derived by applying the concept of the oral disposition index to measurements obtained during the 2-h OGTT and calculated as the index of insulin secretion factored by insulin sensitivity (ΔINS/ΔPG 30 x Matsuda SIOGTT) from the OGTT. A higher score shows improved pancreatic insulin responsiveness relative to resistance. (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | index score (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 471 |
| Dapagliflozin (DAPA) | 311 |
| EQW Plus DAPA | 503 |
| Dapagliflozin Plus Glucophage (MET ER) | 395 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 545 |
Treatment effect on SBP after 24 weeks of treatment (NCT02635386)
Timeframe: 24 weeks treatment
| Intervention | mmHg (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 123.6 |
| Dapagliflozin (DAPA) | 123 |
| EQW Plus DAPA | 122 |
| Dapagliflozin Plus Glucophage (MET ER) | 128 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 124 |
Treatment impact on percent total body fat by DEXA (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | percent fat mass (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 46.1 |
| Dapagliflozin (DAPA) | 46.4 |
| EQW Plus DAPA | 45.8 |
| Dapagliflozin Plus Glucophage (MET ER) | 46.1 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 45.2 |
Treatment effect on blood concentrations of total cholesterol (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 189 |
| Dapagliflozin (DAPA) | 186 |
| EQW Plus DAPA | 185 |
| Dapagliflozin Plus Glucophage (MET ER) | 192 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 178 |
Treatment impact on total fat mass by DEXA (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | kilogram (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 47.6 |
| Dapagliflozin (DAPA) | 47.8 |
| EQW Plus DAPA | 45.9 |
| Dapagliflozin Plus Glucophage (MET ER) | 48 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 44.5 |
Treatment effect on blood concentrations of total testosterone (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | ng/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 38.8 |
| Dapagliflozin (DAPA) | 35 |
| EQW Plus DAPA | 42.6 |
| Dapagliflozin Plus Glucophage (MET ER) | 39.5 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 45.5 |
Treatment effect on blood concentrations of triglycerides (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 130 |
| Dapagliflozin (DAPA) | 132 |
| EQW Plus DAPA | 112 |
| Dapagliflozin Plus Glucophage (MET ER) | 105 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 110 |
Treatment impact on trunk/limb ratio (measure of central adiposity) by DEXA (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | ratio (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 1.03 |
| Dapagliflozin (DAPA) | .95 |
| EQW Plus DAPA | .93 |
| Dapagliflozin Plus Glucophage (MET ER) | .98 |
| Phentermine /Topiramate (PHEN/ TPM) ER | .99 |
Treatment impact on WHtR which is a measure of central adiposity (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | ratio (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | .64 |
| Dapagliflozin (DAPA) | .61 |
| EQW Plus DAPA | .65 |
| Dapagliflozin Plus Glucophage (MET ER) | .61 |
| Phentermine /Topiramate (PHEN/ TPM) ER | .59 |
Treatment impact on central adiposity after 24 weeks (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | ratio (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | .83 |
| Dapagliflozin (DAPA) | .79 |
| EQW Plus DAPA | .86 |
| Dapagliflozin Plus Glucophage (MET ER) | .83 |
| Phentermine /Topiramate (PHEN/ TPM) ER | .81 |
The nine common serotonergic AEs were headache, dizziness, nausea, fatigue, dry mouth, diarrhea, vomiting, insomnia, and/or anxiety. (NCT01987427)
Timeframe: Baseline up to Week 12 (end of treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| Lorcaserin 10 mg BID + Phentermine Placebo BID | 37.2 |
| Lorcaserin 10mg BID+Phentermine 15mg QD+Phentermine Placebo QD | 42.3 |
| Lorcaserin 10 mg BID + Phentermine 15 mg BID | 40.5 |
(NCT01987427)
Timeframe: Week 12 (end of treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| Lorcaserin 10 mg BID + Phentermine Placebo BID | 28.2 |
| Lorcaserin 10mg BID+Phentermine 15mg QD+Phentermine Placebo QD | 59.0 |
| Lorcaserin 10 mg BID + Phentermine 15 mg BID | 70.9 |
(NCT01987427)
Timeframe: Baseline and Week 12 (end of treatment)
| Intervention | centimeter (cm) (Mean) | |||
|---|---|---|---|---|
| Waist Circumference: Baseline | Waist Circumference: Change at Week 12 | Hip Circumference: Baseline | Hip Circumference: Change at Week 12 | |
| Lorcaserin 10 mg BID + Phentermine 15 mg BID | 114.0 | -7.1 | 125.4 | -6.2 |
| Lorcaserin 10 mg BID + Phentermine Placebo BID | 112.2 | -3.4 | 124.1 | -2.8 |
| Lorcaserin 10mg BID+Phentermine 15mg QD+Phentermine Placebo QD | 112.2 | -4.7 | 123.7 | -3.6 |
(NCT01987427)
Timeframe: Baseline and Week 12 (end of treatment)
| Intervention | ratio (Mean) | |
|---|---|---|
| Baseline | Change at Week 12 | |
| Lorcaserin 10 mg BID + Phentermine 15 mg BID | 0.91 | -0.01 |
| Lorcaserin 10 mg BID + Phentermine Placebo BID | 0.91 | -0.01 |
| Lorcaserin 10mg BID+Phentermine 15mg QD+Phentermine Placebo QD | 0.91 | -0.01 |
(NCT01987427)
Timeframe: Baseline, Weeks 1, 2, 4, 8 and 12
| Intervention | kilogram (kg) (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline | Change at Week 1 | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | |
| Lorcaserin 10 mg BID + Phentermine 15 mg BID | 106.63 | -1.97 | -2.94 | -4.44 | -6.33 | -7.55 |
| Lorcaserin 10 mg BID + Phentermine Placebo BID | 105.33 | -0.94 | -1.56 | -2.27 | -2.87 | -3.48 |
| Lorcaserin 10mg BID+Phentermine 15mg QD+Phentermine Placebo QD | 105.04 | -1.36 | -2.43 | -3.81 | -5.76 | -7.00 |
(NCT01987427)
Timeframe: Baseline up to Week 16
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| TEAE | SAE | AEs leading to study drug discontinuation | |
| Lorcaserin 10 mg BID + Phentermine 15 mg BID | 54 | 1 | 9 |
| Lorcaserin 10 mg BID + Phentermine Placebo BID | 50 | 0 | 4 |
| Lorcaserin 10mg BID+Phentermine 15mg QD+Phentermine Placebo QD | 52 | 2 | 2 |
(NCT01987427)
Timeframe: Baseline up to Week 16
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Gamma glutamyl transferase: high | Phosphorus: low | Potassium: high | Total bilirubin: high | Triglycerides: High | Uric acid: high | Hemoglobin: low | Lymphocytes: high | Neutrophils: low | White blood cell (WBC) count: low | |
| Lorcaserin 10 mg BID + Phentermine 15 mg BID | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Lorcaserin 10 mg BID + Phentermine Placebo BID | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 2 | 0 |
| Lorcaserin 10mg BID+Phentermine 15mg QD+Phentermine Placebo QD | 1 | 1 | 3 | 1 | 1 | 0 | 1 | 0 | 1 | 0 |
(NCT01987427)
Timeframe: Baseline, Weeks 1, 2, 4, 8 and 12
| Intervention | percent change (Mean) | ||||
|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 8 | Week 12 | |
| Lorcaserin 10 mg BID + Phentermine 15 mg BID | -1.82 | -2.75 | -4.20 | -6.03 | -7.23 |
| Lorcaserin 10 mg BID + Phentermine Placebo BID | -0.93 | -1.47 | -2.18 | -2.77 | -3.29 |
| Lorcaserin 10mg BID+Phentermine 15mg QD+Phentermine Placebo QD | -1.28 | -2.33 | -3.68 | -5.54 | -6.69 |
(NCT00796367)
Timeframe: From baseline to end of treatment
| Intervention | percent weight loss (Least Squares Mean) |
|---|---|
| Placebo | -1.8 |
| VI-0521 Mid | -9.32 |
| VI-0521 Top | -10.5 |
(NCT00796367)
Timeframe: Baseline to End of Treatment
| Intervention | percent participants (Number) |
|---|---|
| Placebo | 30 |
| VI-0521 Mid | 75.2 |
| VI-0521 Top | 79.3 |
(NCT00554216)
Timeframe: baseline to 56 weeks
| Intervention | percent weight loss (Least Squares Mean) |
|---|---|
| Placebo | 1.55 |
| VI-0521 Low | 5.10 |
| VI-0521 Top | 10.92 |
(NCT00554216)
Timeframe: baseline to 56 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 17.3 |
| VI-0521 Low | 44.9 |
| VI-0521 Top | 66.7 |
(NCT00553787)
Timeframe: Baseline to 56 weeks
| Intervention | percent weight loss (Least Squares Mean) |
|---|---|
| Placebo | 1.24 |
| VI-0521 Mid | 7.81 |
| VI-0521 Top | 9.84 |
(NCT00553787)
Timeframe: Baseline to 56 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 20.8 |
| VI-0521 Mid | 62.1 |
| VI-0521 Top | 70 |
"All sub scales are scored from 0 - 100, with higher scores indicating better health. Each component summary is a normed score with a mean of 50 and standard deviation of 10 in the US general population. Higher scores indicate better health.~Z-scores are computed for each subscale, which are then converted into a component summary z-score using a weighted formula. The component summary z-score is then converted to a t-distribution with a mean of 50 and standard deviation of 10.~Scores are scaled to a T-score with a mean of 50 and standard deviation of 10. Scores above 50 indicate better health." (NCT02911818)
Timeframe: Randomization and 52 weeks
| Intervention | T scores (Mean) |
|---|---|
| CMS-Alone | 0.8 |
| CMS-Liraglutide | 4.5 |
| Multi-Component Intervention | 6.4 |
"All sub scales are scored from 0 - 100, with higher scores indicating better health. Each component summary is a normed score with a mean of 50 and standard deviation of 10 in the US general population. Higher scores indicate better health.~Z-scores are computed for each subscale, which are then converted into a component summary z-score using a weighted formula. The component summary z-score is then converted to a t-distribution with a mean of 50 and standard deviation of 10.~Scores are scaled to a T-score with a mean of 50 and standard deviation of 10. Scores above 50 indicate better health." (NCT02911818)
Timeframe: Randomization and 52 weeks
| Intervention | T scores (Mean) |
|---|---|
| CMS-Alone | 4.4 |
| CMS-Liraglutide | 2.1 |
| Multi-Component Intervention | 3.4 |
(NCT02911818)
Timeframe: Randomization and 52 weeks
| Intervention | mg/L (Mean) |
|---|---|
| CMS-Alone | -0.4 |
| CMS-Liraglutide | -2.0 |
| Multi-Component Intervention | -3.0 |
(NCT02911818)
Timeframe: Randomization and 52 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| CMS-Alone | -3.0 |
| CMS-Liraglutide | -2.9 |
| Multi-Component Intervention | -3.5 |
(NCT02911818)
Timeframe: Randomization and 52 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| CMS-Alone | 0.01 |
| CMS-Liraglutide | -5.2 |
| Multi-Component Intervention | -5.7 |
(NCT02911818)
Timeframe: Randomization and 52 weeks
| Intervention | uIU/mL (Mean) |
|---|---|
| CMS-Alone | -1.5 |
| CMS-Liraglutide | -1.1 |
| Multi-Component Intervention | -1.5 |
(NCT02911818)
Timeframe: Randomization and 52 weeks
| Intervention | percentage (Mean) |
|---|---|
| CMS-Alone | -0.3 |
| CMS-Liraglutide | -0.5 |
| Multi-Component Intervention | -0.6 |
(NCT02911818)
Timeframe: Randomization and 52 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| CMS-Alone | -1.3 |
| CMS-Liraglutide | 3.0 |
| Multi-Component Intervention | 2.0 |
(NCT02911818)
Timeframe: Randomization and 52 weeks
| Intervention | Beats per minute (Mean) |
|---|---|
| CMS-Alone | -7.4 |
| CMS-Liraglutide | -5.3 |
| Multi-Component Intervention | 9.7 |
HOMA-IR is a measurement for insulin resistance and is calculated from: fasting insulin (U/L) x fasting glucose (mg/dL)/405. A decrease from baseline to the end of treatment, a negative value, indicates an improvement (NCT02911818)
Timeframe: Randomization and 52 weeks
| Intervention | mg/dL*µIU/mL/405 (Mean) |
|---|---|
| CMS-Alone | -0.4 |
| CMS-Liraglutide | -0.3 |
| Multi-Component Intervention | -0.4 |
(NCT02911818)
Timeframe: Randomization and 52 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| CMS-Alone | -3.3 |
| CMS-Liraglutide | -9.6 |
| Multi-Component Intervention | -9.4 |
PHQ-9 is scored based on a 0-27 scale in which higher scores indicate more severe depression. Values are summed to compute the total score. (NCT02911818)
Timeframe: Randomization and 52 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| CMS-Alone | -1.8 |
| CMS-Liraglutide | -1.9 |
| Multi-Component Intervention | -1.5 |
(NCT02911818)
Timeframe: Randomization and 52 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| CMS-Alone | -14.1 |
| CMS-Liraglutide | -13.3 |
| Multi-Component Intervention | -15.3 |
(NCT02911818)
Timeframe: Randomization and 52 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| CMS-Alone | -7.0 |
| CMS-Liraglutide | -9.7 |
| Multi-Component Intervention | -10.0 |
(NCT02911818)
Timeframe: Randomization and 52 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| CMS-Alone | -16.3 |
| CMS-Liraglutide | -21.3 |
| Multi-Component Intervention | -14.4 |
(NCT02911818)
Timeframe: Randomization and 52 weeks
| Intervention | cm (Mean) |
|---|---|
| CMS-Alone | -6.5 |
| CMS-Liraglutide | -11.1 |
| Multi-Component Intervention | -12.6 |
(NCT02911818)
Timeframe: Re-randomization and 12 weeks
| Intervention | percent change (Mean) |
|---|---|
| 12-Week Extension Study: Phentermine Group | -1.6 |
| 12-Week Extension Study: Placebo Group | -0.1 |
(NCT02911818)
Timeframe: Re-randomization and 12 weeks
| Intervention | mg/L (Mean) |
|---|---|
| 12-Week Extension Study: Placebo Group | -0.8 |
| 12-Week Extension Study: Phentermine Group | -0.6 |
(NCT02911818)
Timeframe: Re-randomization and 12 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| 12-Week Extension Study: Phentermine Group | 1.3 |
| 12-Week Extension Study: Placebo Group | 0.2 |
(NCT02911818)
Timeframe: Re-randomization and 12 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| 12-Week Extension Study: Placebo Group | 1.4 |
| 12-Week Extension Study: Phentermine Group | 6.3 |
(NCT02911818)
Timeframe: Re-randomization and 12 weeks
| Intervention | uIU/mL (Mean) |
|---|---|
| 12-Week Extension Study: Placebo Group | 0.2 |
| 12-Week Extension Study: Phentermine Group | 0.5 |
(NCT02911818)
Timeframe: Re-randomization and 12 weeks
| Intervention | percentage (Mean) |
|---|---|
| 12-Week Extension Study: Placebo Group | 0.0 |
| 12-Week Extension Study: Phentermine Group | 0.0 |
(NCT02911818)
Timeframe: Re-randomization and 12 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| 12-Week Extension Study: Placebo Group | 0.6 |
| 12-Week Extension Study: Phentermine Group | 2.0 |
(NCT02911818)
Timeframe: Re-randomization and 12 weeks
| Intervention | Beats per minute (Mean) |
|---|---|
| 12-Week Extension Study: Placebo Group | 0 |
| 12-Week Extension Study: Phentermine Group | 2.1 |
HOMA-IR is a measurement for insulin resistance and is calculated from: fasting insulin (U/L) x fasting glucose (mg/dL)/405. A decrease from baseline to the end of treatment, a negative value, indicates an improvement (NCT02911818)
Timeframe: Re-randomization and 12 weeks
| Intervention | mg/dL*µIU/mL/405 (Mean) |
|---|---|
| 12-Week Extension Study: Placebo Group | 0.1 |
| 12-Week Extension Study: Phentermine Group | 0.3 |
(NCT02911818)
Timeframe: Re-randomization and 12 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| 12-Week Extension Study: Placebo Group | 2.3 |
| 12-Week Extension Study: Phentermine Group | -2.4 |
(NCT02911818)
Timeframe: Re-randomization and 12 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| 12-Week Extension Study: Placebo Group | 1.2 |
| 12-Week Extension Study: Phentermine Group | 2.0 |
(NCT02911818)
Timeframe: Re-randomization and 12 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| 12-Week Extension Study: Placebo Group | 3.4 |
| 12-Week Extension Study: Phentermine Group | 0.4 |
(NCT02911818)
Timeframe: Re-randomization and 12 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| 12-Week Extension Study: Placebo Group | 4.1 |
| 12-Week Extension Study: Phentermine Group | 6.6 |
(NCT02911818)
Timeframe: Re-randomization and 12 weeks
| Intervention | cm (Mean) |
|---|---|
| 12-Week Extension Study: Placebo Group | -0.6 |
| 12-Week Extension Study: Phentermine Group | -0.4 |
PHQ-9 is scored based on a 0-27 scale in which higher scores indicate more severe depression. Values are summed to compute the total score. (NCT02911818)
Timeframe: Re-randomization and 12 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| 12-Week Extension Study: Placebo Group | 0.2 |
| 12-Week Extension Study: Phentermine Group | 0.0 |
"All sub scales are scored from 0 - 100, with higher scores indicating better health. Each component summary is a normed score with a mean of 50 and standard deviation of 10 in the US general population. Higher scores indicate better health.~Z-scores are computed for each subscale, which are then converted into a component summary z-score using a weighted formula. The component summary z-score is then converted to a t-distribution with a mean of 50 and standard deviation of 10.~Scores are scaled to a T-score with a mean of 50 and standard deviation of 10. Scores above 50 indicate better health." (NCT02911818)
Timeframe: Re-randomization and 12 weeks
| Intervention | T scores (Mean) |
|---|---|
| 12-Week Extension Study: Placebo Group | -0.1 |
| 12-Week Extension Study: Phentermine Group | 0.2 |
"All sub scales are scored from 0 - 100, with higher scores indicating better health. Each component summary is a normed score with a mean of 50 and standard deviation of 10 in the US general population. Higher scores indicate better health.~Z-scores are computed for each subscale, which are then converted into a component summary z-score using a weighted formula. The component summary z-score is then converted to a t-distribution with a mean of 50 and standard deviation of 10.~Scores are scaled to a T-score with a mean of 50 and standard deviation of 10. Scores above 50 indicate better health." (NCT02911818)
Timeframe: Re-randomization and 12 weeks
| Intervention | T scores (Mean) |
|---|---|
| 12-Week Extension Study: Placebo Group | 0.3 |
| 12-Week Extension Study: Phentermine Group | -1.2 |
(NCT02911818)
Timeframe: Randomization and 52 weeks
| Intervention | percent change (Mean) |
|---|---|
| CMS-Alone | -6.1 |
| CMS-Liraglutide | -11.5 |
| Multi-Component Intervention | -11.8 |
(NCT00600067)
Timeframe: Baseline to 56 weeks
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo | -1.2 |
| VI-0521 | -1.56 |
(NCT00600067)
Timeframe: Baseline to 56 weeks
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo | -2.71 |
| VI-0521 | -9.41 |
40 reviews available for phentermine and Weight Reduction
| Article | Year |
|---|---|
Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association.
Topics: American Heart Association; Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Exercise; | 2021 |
Benefits of weight loss of 10% or more in patients with overweight or obesity: A review.
Topics: Anti-Obesity Agents; Diabetes Mellitus, Type 2; Humans; Obesity; Overweight; Phentermine; Quality of | 2022 |
Phentermine/Topiramate: Pediatric First Approval.
Topics: Adolescent; Adult; Anti-Obesity Agents; Child; Delayed-Action Preparations; Diabetes Mellitus, Type | 2022 |
Comprehensive Review of Current and Upcoming Anti-Obesity Drugs.
Topics: Anti-Obesity Agents; Benzazepines; Humans; Orlistat; Phentermine; Weight Loss | 2020 |
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Topics: Animals; Anti-Obesity Agents; Benzazepines; Bupropion; Humans; Liraglutide; Naltrexone; Obesity; Orl | 2021 |
Use of Weight Loss Medications in Patients after Bariatric Surgery.
Topics: Anti-Obesity Agents; Bariatric Surgery; Humans; Liraglutide; Obesity; Phentermine; Postoperative Per | 2021 |
Efficacy and Safety of Phentermine/Topiramate in Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis.
Topics: Adult; Blood Pressure; Body Weight; Drug Therapy, Combination; Female; Fructose; Humans; Male; Middl | 2021 |
Intensive management of obesity in people with severe chronic kidney disease: A review.
Topics: Bariatric Surgery; Diabetes Mellitus, Type 2; Humans; Obesity; Phentermine; Renal Insufficiency, Chr | 2021 |
Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review.
Topics: Adult; Anti-Obesity Agents; Humans; Orlistat; Phentermine; State Medicine; Weight Loss | 2021 |
Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.
Topics: Anti-Obesity Agents; Benzazepines; Clinical Trials as Topic; Fructose; Humans; Life Style; Liragluti | 2017 |
Pharmacotherapy for obesity in individuals with type 2 diabetes.
Topics: Anti-Obesity Agents; Benzazepines; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Compoun | 2018 |
Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options.
Topics: Anti-Obesity Agents; Benzazepines; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Lirag | 2019 |
Phentermine and topiramate extended-release for the obesity: new kids on the block.
Topics: Animals; Anti-Obesity Agents; Cardiovascular Diseases; Delayed-Action Preparations; Drug Combination | 2013 |
Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management.
Topics: Anti-Obesity Agents; Delayed-Action Preparations; Fructose; Humans; Obesity; Overweight; Phentermine | 2013 |
Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Benzazepines; Body Weight; Clinical Trials, Phase | 2013 |
Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?
Topics: Anti-Obesity Agents; Bariatric Surgery; Benzazepines; Benzhydryl Compounds; Blood Glucose; Diabetes | 2014 |
Obesity consults--comprehensive obesity management in 2013: understanding the shifting paradigm.
Topics: Anti-Obesity Agents; Bariatric Surgery; Clinical Trials as Topic; Diet, Reducing; Drug Therapy, Comb | 2013 |
Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity.
Topics: Aged; Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Clinical Trials, Phase III | 2014 |
Combination phentermine/topiramate for obesity treatment in primary care: a review.
Topics: Anti-Obesity Agents; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Combina | 2014 |
Overview of new antiobesity drugs.
Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Fructose; Glucagon-Li | 2014 |
Lifestyle management for enhancing outcomes after bariatric surgery.
Topics: Appetite Depressants; Bariatric Surgery; Behavior Therapy; Comorbidity; Diabetes Mellitus, Type 2; D | 2014 |
Medical treatment of obesity: the past, the present and the future.
Topics: Anti-Obesity Agents; Benzazepines; Drug Therapy, Combination; Fructose; Humans; Lactones; Obesity; O | 2014 |
Efficacy comparison of medications approved for chronic weight management.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Benzazepines; Body Weight; Clinical Trials as Topi | 2015 |
Safety and tolerability of medications approved for chronic weight management.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Delayed-Action Preparations; Drug-Related Side Effects | 2015 |
Combination phentermine and topiramate extended release in the management of obesity.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Clinical Trials, P | 2015 |
A Comparison of New Pharmacological Agents for the Treatment of Obesity.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Drug Combinations | 2016 |
Long-term effects of weight-reducing drugs in people with hypertension.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Cyclobutanes; Diet, Reducing; Fema | 2016 |
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Topics: Anti-Obesity Agents; Bayes Theorem; Benzazepines; Drug Combinations; Female; Fructose; Humans; Lacto | 2016 |
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Topics: Anti-Obesity Agents; Bayes Theorem; Benzazepines; Drug Combinations; Female; Fructose; Humans; Lacto | 2016 |
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Topics: Anti-Obesity Agents; Bayes Theorem; Benzazepines; Drug Combinations; Female; Fructose; Humans; Lacto | 2016 |
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Topics: Anti-Obesity Agents; Bayes Theorem; Benzazepines; Drug Combinations; Female; Fructose; Humans; Lacto | 2016 |
In brief: Phentermine (Lomaira) for weight loss.
Topics: Anti-Obesity Agents; Drug Approval; Humans; Obesity; Phentermine; Weight Loss | 2016 |
Pharmacologic therapies for obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Cyclobutanes; | 2010 |
Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Topics: Adipose Tissue; Adiposity; Animals; Anti-Obesity Agents; Appetite Depressants; Appetite Regulation; | 2010 |
Obesity in adults.
Topics: Adult; Diethylpropion; Gastric Bypass; Gastroplasty; Humans; Obesity; Obesity, Morbid; Phentermine; | 2011 |
Recent advancements in drug treatment of obesity.
Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Combinati | 2012 |
Weight loss medications--where do they fit in?
Topics: Anti-Obesity Agents; Chronic Disease; Cyclobutanes; Diethylpropion; Humans; Lactones; Obesity; Orlis | 2006 |
Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors.
Topics: Caloric Restriction; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus; Diet; Diet, Fat-Restr | 2006 |
Pharmacological approaches to intervention.
Topics: Anti-Obesity Agents; Appetite Depressants; Fenfluramine; Humans; Obesity; Phentermine; Time Factors; | 1997 |
The fenfluramine/phentermine combination for weight loss.
Topics: Appetite Depressants; Clinical Trials as Topic; Drug Therapy, Combination; Fenfluramine; Humans; Phe | 1997 |
Obesity.
Topics: Appetite Depressants; Behavior; Body Mass Index; Diet, Reducing; Exercise; Female; Fenfluramine; Hum | 1998 |
The use of pharmacologic agents in the treatment of the obese patient.
Topics: Anti-Obesity Agents; Body Mass Index; Cyclobutanes; Female; Follow-Up Studies; Humans; Lactones; Mal | 1999 |
[The obesity epidemics--do diet pills have a place in the treatment?].
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Fenfluramine; Humans; Lactones; Leptin; Obe | 2000 |
28 trials available for phentermine and Weight Reduction
| Article | Year |
|---|---|
The Effect of Orlistat on Sterol Metabolism in Obese Patients.
Topics: Adult; Anti-Obesity Agents; Cholesterol; Double-Blind Method; Humans; Lactones; Lipase; Obesity; Orl | 2022 |
The use of virtual visits for obesity pharmacotherapy in patients with overweight or obesity compared with in-person encounters.
Topics: Adult; Humans; Obesity; Overweight; Phentermine; Prospective Studies; Weight Loss | 2022 |
Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
Topics: Adolescent; Adult; Benzhydryl Compounds; Blood Glucose; Drug Therapy, Combination; Exenatide; Female | 2021 |
Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study.
Topics: Adolescent; Adult; Anti-Obesity Agents; Benzazepines; Double-Blind Method; Female; Humans; Male; Mid | 2017 |
Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
Topics: Adult; Aged; Anti-Obesity Agents; Appetite; Appetite Depressants; Double-Blind Method; Drug Therapy, | 2019 |
Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
Topics: Adult; Aged; Anti-Obesity Agents; Appetite; Appetite Depressants; Double-Blind Method; Drug Therapy, | 2019 |
Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
Topics: Adult; Aged; Anti-Obesity Agents; Appetite; Appetite Depressants; Double-Blind Method; Drug Therapy, | 2019 |
Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
Topics: Adult; Aged; Anti-Obesity Agents; Appetite; Appetite Depressants; Double-Blind Method; Drug Therapy, | 2019 |
Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
Topics: Adult; Aged; Anti-Obesity Agents; Appetite; Appetite Depressants; Double-Blind Method; Drug Therapy, | 2019 |
Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
Topics: Adult; Aged; Anti-Obesity Agents; Appetite; Appetite Depressants; Double-Blind Method; Drug Therapy, | 2019 |
Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
Topics: Adult; Aged; Anti-Obesity Agents; Appetite; Appetite Depressants; Double-Blind Method; Drug Therapy, | 2019 |
Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
Topics: Adult; Aged; Anti-Obesity Agents; Appetite; Appetite Depressants; Double-Blind Method; Drug Therapy, | 2019 |
Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
Topics: Adult; Aged; Anti-Obesity Agents; Appetite; Appetite Depressants; Double-Blind Method; Drug Therapy, | 2019 |
Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults.
Topics: Adult; Anti-Obesity Agents; Delayed-Action Preparations; Drug Combinations; Female; Fructose; Humans | 2013 |
Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; D | 2014 |
Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; D | 2014 |
Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; D | 2014 |
Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; D | 2014 |
Greater hunger and less restraint predict weight loss success with phentermine treatment.
Topics: Adult; Appetite; Breakfast; Feeding Behavior; Female; Humans; Hunger; Male; Middle Aged; Obesity; Ph | 2016 |
Effects of a meal replacement system alone or in combination with phentermine on weight loss and food cravings.
Topics: Adult; Appetite Depressants; Combined Modality Therapy; Craving; Double-Blind Method; Female; Humans | 2016 |
Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.
Topics: Adolescent; Adult; Appetite Depressants; Blood Pressure; Cyclobutanes; Drug Therapy, Combination; Fe | 2010 |
Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity.
Topics: Adult; Appetite Depressants; Delayed-Action Preparations; Diabetic Angiopathies; Double-Blind Method | 2010 |
Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Comorbidity; Double-Blind Method; Drug Combinations; F | 2011 |
Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Blood Glucose; Blood Pressure; Body Weight; Delayed-Ac | 2012 |
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
Topics: Adult; Anti-Obesity Agents; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus; | 2012 |
Comparison of continuous and intermittent anorectic therapy in obesity.
Topics: Adult; Appetite Depressants; Double-Blind Method; Female; Humans; Middle Aged; Obesity; Phentermine; | 1968 |
Beneficial effects of weight loss on plasma apolipoproteins in postmenopausal women.
Topics: Adult; Aged; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins B; Apolipoproteins C; Apolipopro | 2004 |
Effects on weight reduction and safety of short-term phentermine administration in Korean obese people.
Topics: Adult; Appetite Depressants; Double-Blind Method; Female; Humans; Korea; Male; Obesity; Phentermine; | 2006 |
Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach.
Topics: Adult; Affect; Appetite Depressants; Behavior Therapy; Feeding Behavior; Female; Fenfluramine; Human | 1997 |
Pharmacologic induction of weight loss to treat type 2 diabetes.
Topics: Appetite Depressants; Behavior Therapy; Blood Glucose; Blood Pressure; Diabetes Mellitus; Diabetes M | 1999 |
Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine.
Topics: Adrenergic Agents; Adult; Appetite Depressants; Body Mass Index; Double-Blind Method; Echocardiograp | 1999 |
Initial weight loss as a predictor of response to obesity drugs.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Drug Therapy, Combination; Female; Fenfluramine; H | 1999 |
Weight loss is correlated with an improved lipoprotein profile in obese postmenopausal women.
Topics: Adult; Aged; Appetite Depressants; Body Composition; Body Constitution; Body Mass Index; Cholesterol | 2000 |
Effect of a weight-reduction program on total and regional body composition in obese postmenopausal women.
Topics: Absorptiometry, Photon; Adult; Aged; Appetite Depressants; Body Composition; Body Constitution; Body | 2000 |
Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study.
Topics: Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Fenfluramine; Follow-Up St | 1992 |
Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo.
Topics: Adult; Behavior Therapy; Blood Pressure; Body Weight; Diet, Reducing; Double-Blind Method; Exercise; | 1992 |
Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise.
Topics: Adult; Behavior Therapy; Blood Pressure; Combined Modality Therapy; Diet, Reducing; Drug Therapy, Co | 1992 |
Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine.
Topics: Adult; Blood Pressure; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fem | 1992 |
Long-term weight control study. VI. Individual participant response patterns.
Topics: Adult; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fenflur | 1992 |
70 other studies available for phentermine and Weight Reduction
| Article | Year |
|---|---|
Drugs for Treating Obesity.
Topics: Anti-Obesity Agents; Humans; Islet Amyloid Polypeptide; Obesity; Phentermine; Weight Loss | 2022 |
Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience.
Topics: Adult; Anti-Obesity Agents; Female; Humans; Male; Middle Aged; Obesity; Phentermine; Topiramate; Wei | 2022 |
Prevalence of Antiobesity Treatment and Weight-Inducing Antihyperglycemic Agents Among Patients With Type 2 Diabetes in the United States.
Topics: Adult; Anti-Obesity Agents; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liraglutide; Nut | 2022 |
Intensive management of obesity in people with Prader-Willi syndrome.
Topics: Child; Humans; Liraglutide; Obesity; Phentermine; Prader-Willi Syndrome; Retrospective Studies; Topi | 2022 |
Real-World Experience of the Efficacy and Safety of Phentermine Use in Adolescents: A Case Series.
Topics: Adolescent; Anti-Obesity Agents; Child; Female; Humans; Pediatric Obesity; Phentermine; Retrospectiv | 2023 |
In brief: Semaglutide (Wegovy) for weight loss in children.
Topics: Anti-Obesity Agents; Child; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Humans; Obesity; Phen | 2023 |
Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy.
Topics: Anti-Obesity Agents; Contraceptive Agents; Female; Fructose; Humans; Obesity; Phentermine; Pregnancy | 2023 |
Combining transoral outlet reduction with pharmacotherapy yields similar 1-year efficacy with improved safety compared with surgical revision for weight regain after Roux-en-Y gastric bypass (with videos).
Topics: Gastric Bypass; Humans; Phentermine; Reoperation; Retrospective Studies; Topiramate; Weight Gain; We | 2023 |
Effect of JumpstartMD, a Commercial Low-Calorie Low-Carbohydrate Physician-Supervised Weight Loss Program, on 22,407 Adults.
Topics: Adult; Aged; Diet, Reducing; Dietary Carbohydrates; Female; Humans; Male; Middle Aged; Obesity; Phen | 2020 |
A Retrospective Study Examining Phentermine on Preconception Weight Loss and Pregnancy Outcomes.
Topics: Adolescent; Adult; Anti-Obesity Agents; Female; Humans; Middle Aged; Phentermine; Pregnancy; Pregnan | 2020 |
Weight Loss Supplement-Induced Pulmonary Hypertension: A Decades Delayed Presentation of Fenfluramine-Phentermine.
Topics: Fenfluramine; Humans; Hypertension, Pulmonary; Obesity; Phentermine; Weight Loss | 2023 |
Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Clinical Trials, Phase III as Topic; Delayed-Action Prepa | 2017 |
Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Clinical Trials, Phase III as Topic; Delayed-Action Prepa | 2017 |
Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Clinical Trials, Phase III as Topic; Delayed-Action Prepa | 2017 |
Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Clinical Trials, Phase III as Topic; Delayed-Action Prepa | 2017 |
Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Clinical Trials, Phase III as Topic; Delayed-Action Prepa | 2017 |
Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Clinical Trials, Phase III as Topic; Delayed-Action Prepa | 2017 |
Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Clinical Trials, Phase III as Topic; Delayed-Action Prepa | 2017 |
Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Clinical Trials, Phase III as Topic; Delayed-Action Prepa | 2017 |
Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Clinical Trials, Phase III as Topic; Delayed-Action Prepa | 2017 |
Observational Comparative Effectiveness of Pharmaceutical Treatments for Obesity within the Veterans Health Administration.
Topics: Adult; Aged; Anti-Obesity Agents; Benzazepines; Body Weight; Cohort Studies; Delayed-Action Preparat | 2018 |
Cardiovascular Safety During and After Use of Phentermine and Topiramate.
Topics: Adolescent; Adult; Anti-Obesity Agents; Drug Combinations; Female; Heart Rate; Hospitalization; Huma | 2019 |
Determining the Effects of Combined Liraglutide and Phentermine on Metabolic Parameters, Blood Pressure, and Heart Rate in Lean and Obese Male Mice.
Topics: Animals; Anti-Obesity Agents; Blood Pressure; Body Weight; Drug Therapy, Combination; Heart Rate; Li | 2019 |
Safety and Effectiveness of Longer-Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort.
Topics: Adolescent; Adult; Anti-Obesity Agents; Cardiovascular Diseases; Cause of Death; Cohort Studies; Ele | 2019 |
Knowledge Gaps in Long-Term Phentermine Use: Making the Case for Maintenance.
Topics: Appetite Depressants; Cohort Studies; Electronic Health Records; Humans; Phentermine; Weight Loss | 2019 |
Response to "Knowledge Gaps in Long-Term Phentermine Use".
Topics: Appetite Depressants; Cohort Studies; Electronic Health Records; Humans; Phentermine; Weight Loss | 2019 |
New medications for weight loss.
Topics: Appetite Depressants; Benzazepines; Drug Combinations; Fructose; Humans; Obesity; Overweight; Phente | 2012 |
Addiction potential of phentermine prescribed during long-term treatment of obesity.
Topics: Adult; Aged; Aged, 80 and over; Appetite Depressants; Behavior, Addictive; Drug Administration Sched | 2014 |
Addiction potential of phentermine prescribed during long-term treatment of obesity.
Topics: Adult; Aged; Aged, 80 and over; Appetite Depressants; Behavior, Addictive; Drug Administration Sched | 2014 |
Addiction potential of phentermine prescribed during long-term treatment of obesity.
Topics: Adult; Aged; Aged, 80 and over; Appetite Depressants; Behavior, Addictive; Drug Administration Sched | 2014 |
Addiction potential of phentermine prescribed during long-term treatment of obesity.
Topics: Adult; Aged; Aged, 80 and over; Appetite Depressants; Behavior, Addictive; Drug Administration Sched | 2014 |
High demand likely for prescription weight-control drugs.
Topics: Appetite Depressants; Benzazepines; Drug Utilization; Fructose; Humans; Obesity; Phentermine; Prescr | 2012 |
Time series analyses of the effect of FDA communications on use of prescription weight loss medications.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Cohort Studies; Cyclobutanes; Dr | 2014 |
Novel point estimation from a semiparametric ratio estimator (SPRE): long-term health outcomes from short-term linear data, with application to weight loss in obesity.
Topics: Appetite Depressants; Biometry; Humans; Longitudinal Studies; Models, Statistical; Obesity; Phenterm | 2013 |
The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?
Topics: Anti-Obesity Agents; Benzazepines; Female; Fructose; Humans; Male; Obesity; Phentermine; Product Sur | 2014 |
Cost-Effectiveness Analysis of Qsymia for Weight Loss.
Topics: Anti-Obesity Agents; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Combinations; | 2015 |
Drug treatment of obesity.
Topics: Anti-Obesity Agents; Benzazepines; Female; Fructose; Humans; Male; Obesity; Phentermine; Weight Loss | 2014 |
Drug treatment of obesity.
Topics: Anti-Obesity Agents; Benzazepines; Female; Fructose; Humans; Male; Obesity; Phentermine; Weight Loss | 2014 |
Drug treatment of obesity--reply.
Topics: Anti-Obesity Agents; Benzazepines; Female; Fructose; Humans; Male; Obesity; Phentermine; Weight Loss | 2014 |
Combination phentermine and topiramate for weight maintenance: the first Australian experience.
Topics: Anti-Obesity Agents; Australia; Body Mass Index; Drug Therapy, Combination; Follow-Up Studies; Fruct | 2014 |
Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out.
Topics: Benzazepines; Bupropion; Drug Combinations; Drug Prescriptions; Fructose; Humans; Naltrexone; Obesit | 2014 |
D1 and D2 antagonists reverse the effects of appetite suppressants on weight loss, food intake, locomotion, and rebalance spiking inhibition in the rat NAc shell.
Topics: Action Potentials; Animals; Appetite Depressants; Benzazepines; Bupropion; Diethylpropion; Dopamine | 2015 |
Health-related quality of life in two randomized controlled trials of phentermine/topiramate for obesity: What mediates improvement?
Topics: Adult; Body Mass Index; Body Weight; Depression; Female; Fructose; Health Status; Humans; Male; Midd | 2016 |
Pharmacotherapy in Conjunction with a Diet and Exercise Program for the Treatment of Weight Recidivism or Weight Loss Plateau Post-bariatric Surgery: a Retrospective Review.
Topics: Adult; Anti-Obesity Agents; Bariatric Surgery; Diet, Reducing; Exercise Therapy; Female; Fructose; H | 2016 |
Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Guidelines as Topic; Humans; Lactones | 2016 |
Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s.
Topics: Anti-Obesity Agents; Benzhydryl Compounds; Databases, Factual; Drug Prescriptions; Glucosides; Human | 2016 |
Effect of phentermine on weight reduction in a pediatric weight management clinic.
Topics: Adolescent; Anti-Obesity Agents; Behavior Therapy; Diet, Reducing; Female; Humans; Male; Minnesota; | 2017 |
Obesity Epidemic: Pharmaceutical Weight Loss.
Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Drug Combinations; Fructose; Humans; | 2017 |
Effectiveness of Medifast supplements combined with obesity pharmacotherapy: a clinical program evaluation.
Topics: Adult; Appetite Depressants; Body Mass Index; Combined Modality Therapy; Delayed-Action Preparations | 2008 |
How physician obesity specialists use drugs to treat obesity.
Topics: 5-Hydroxytryptophan; Anti-Obesity Agents; Carbidopa; Drug Combinations; Drug Labeling; Drug Therapy, | 2009 |
Why the attitude?
Topics: Appetite Depressants; Diet, Reducing; Exercise; Humans; Life Style; Obesity; Phentermine; Weight Los | 2009 |
A case of profound weight loss secondary to use of phentermine.
Topics: Adult; Appetite Depressants; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, | 2009 |
Posterior reversible encephalopathy syndrome in the context of phentermine use resulting in intracranial hemorrhage.
Topics: Adult; Encephalitis; Female; Humans; Intracranial Hemorrhages; Phentermine; Seizures; Syndrome; Weig | 2011 |
Combination treatment to CONQUER obesity?
Topics: Anti-Obesity Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combination | 2011 |
Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity.
Topics: Adult; Anti-Obesity Agents; Blood Pressure; Cohort Studies; Diet, Carbohydrate-Restricted; Diet, Ket | 2011 |
Appetite suppressants as adjuncts for weight loss.
Topics: Appetite Depressants; Cardiovascular Diseases; Chemotherapy, Adjuvant; Diethylpropion; Evidence-Base | 2011 |
Obesity and type 2 diabetes mellitus in South Dakota: focused insight into prevalence, physiology and treatment.
Topics: Adipocytes; Adrenergic Agents; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Ob | 2011 |
Phentermine plus topiramate in the treatment of obesity.
Topics: Anti-Obesity Agents; Drug Combinations; Fructose; Heart Valve Diseases; Humans; Obesity; Phentermine | 2011 |
Phentermine plus topiramate in the treatment of obesity.
Topics: Anti-Obesity Agents; Drug Combinations; Fructose; Humans; Obesity; Phentermine; Topiramate; United S | 2011 |
Phentermine therapy for obesity does not elevate blood pressure.
Topics: Appetite Depressants; Delayed-Action Preparations; Diabetic Angiopathies; Dyslipidemias; Female; Hum | 2011 |
What cost weight loss?
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cyclobutanes; Fructose; Humans; Naltrexone; Obesity; P | 2012 |
Obesity and cardiovascular disease.
Topics: Adult; Anti-Obesity Agents; Atrial Fibrillation; Bariatric Surgery; Cardiovascular Diseases; Diabete | 2012 |
ACS chemical neuroscience molecule spotlight on Qnexa.
Topics: Anti-Obesity Agents; Appetite Depressants; Clinical Trials, Phase III as Topic; Comorbidity; Double- | 2011 |
Two anti-obesity hopefuls and their safety.
Topics: Adult; Anti-Obesity Agents; Benzazepines; Dose-Response Relationship, Drug; Drug Combinations; Drugs | 2012 |
Off-label medication use.
Topics: Anti-Obesity Agents; Anticonvulsants; Bipolar Disorder; Child; Delayed-Action Preparations; Drug App | 2012 |
2 new drugs for weight loss.
Topics: Anti-Obesity Agents; Benzazepines; Drug Combinations; Drug Interactions; Fructose; Humans; Obesity; | 2012 |
Phentermine: an appetite-suppressant amphetamine classified as a narcotic in France. Is a combination with topiramate on the horizon?
Topics: Anti-Obesity Agents; Appetite Depressants; Appetite Regulation; Drug and Narcotic Control; Drug Comb | 2012 |
The FDA's assessment of two drugs for chronic weight management.
Topics: Abnormalities, Drug-Induced; Anti-Obesity Agents; Benzazepines; Delayed-Action Preparations; Drug Ap | 2012 |
Obesity drug pipeline not so fat.
Topics: Agouti-Related Protein; alpha-MSH; Animals; Anti-Obesity Agents; Appetite; Arcuate Nucleus of Hypoth | 2003 |
Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status.
Topics: Adult; Appetite Depressants; Body Mass Index; Drug Therapy, Combination; Fenfluramine; Fluoxetine; H | 2007 |
Successful appetite suppression therapy with fenfluramine and phentermine in the obese diabetic transplant patient.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Diabetic Nephropathies; Diet, Reducing; Drug Therapy, | 1995 |
Anorectic medications in the treatment of obesity.
Topics: Appetite Depressants; Chronic Disease; Drug and Narcotic Control; Humans; Obesity; Ohio; Phentermine | 1994 |
The fen-phen finale: a study of weight loss and valvular heart disease.
Topics: Adult; Affect; Appetite; Behavior Therapy; Drug Therapy, Combination; Echocardiography, Doppler; Fem | 1998 |
After fen-phen.
Topics: Antidepressive Agents, Second-Generation; Appetite Depressants; Consumer Product Safety; Fenfluramin | 1997 |
Lower dosages of phentermine-fenfluramine given in the afternoon: five cases with significant weight loss.
Topics: Adult; Circadian Rhythm; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Combinat | 1999 |
Valvular heart disease in fenfluramine- phentermine-treated patients: a comparison with control patients.
Topics: Appetite Depressants; Body Mass Index; Diet, Reducing; Drug Combinations; Echocardiography; Female; | 1999 |
Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine.
Topics: Aortic Valve Insufficiency; Appetite Depressants; Body Mass Index; Counseling; Dexfenfluramine; Drug | 1999 |
Beneficial effects of pharmacotherapy on weight loss, depressive symptoms, and eating patterns in obese binge eaters and non-binge eaters.
Topics: Adult; Appetite Depressants; Depression; Eating; Feeding and Eating Disorders; Female; Fenfluramine; | 1999 |
Pharmaceutical cost savings of treating obesity with weight loss medications.
Topics: Adolescent; Adult; Appetite Depressants; Caffeine; Cardiovascular Diseases; Diabetes Mellitus; Drug | 1999 |
The relationship between health-related quality of life and weight loss.
Topics: Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Combined Modality Therapy; Drug Therapy, Com | 2001 |
I have tried everything I can think of to lose weight on my own and am now thinking of using weight-loss medications. Are they safe?
Topics: Appetite Depressants; Cyclobutanes; Drug Combinations; Humans; Phentermine; Weight Loss | 2002 |